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Abl   Abelson tyrosine kinase 
Amp   Ampicillin 
ATP   Adenosine triphosphate  
Bcr   Breakpoint cluster region 
BSA   Bovine serum albumine 
CML   Chronic Myelogenous Leukemia 
DNA   Deoxyribonucleic acid 
E. coli   Escherichia coli  
GFP   Green Fluorescense Protein 
IL-3   Interleukin-3 
IPTG   Isopropylthiogalactosidase 
IRES   Internal ribosome entry site 
Kan   Kanamycin 
LB medium  Luria-Bertani Medium 
MCS   Molecular Cloning Site 
PCR    Polymerase Chain Reaction 
Ph chromosome Philadelphia chromosome 
SAP   Shrimp Alkaline Phosphatase  
TAE   Tris Acetate EDTA 
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Chronic myelogenous leukaemia is a monoclonal hematopoetic stem cell disorder 
characterised by the t(9;22) translocation and results in the constitutively activated Bcr-Abl 
tyrosine kinase. Since the tyrosine kinase activity of the Bcr-Abl fusion protein is the 
causative molecular event in CML, targeting the tyrosine kinase activity appears to be an 
attractive therapeutic strategy. 
 
Imatinib, Glivec, is a drug that inhibits the tyrosine kinase activity of Bcr-Abl. By binding to 
the ATP binding pocket, it prevents ATP from binding and the phosphorylation of 
downstream substrates is disrupted. Clinical studies have proven imatinib to be highly 
effective in the treatment of CML and imatinib is now the first-line therapy for all stages of 
CML However; point mutations have been detected in the ATP binding region of the Abl 
kinase domain. These mutations alter the conformation of the ATP binding pocket, disturb the 
binding of imatinib, and lead to imatinib resistance.   
 
We wanted to develop an experimental system where the effects of mutations in Bcr-Abl, 
leading to imatinib resistance, could be studied and new targets for therapy identified. For this 
we were going to clone Bcr-Abl into a pMACS 4-IRES.II vector. The Bcr-Abl gene is large, 
so to get the full-length construct, the cloning strategy involved ligation of PCR fragments in 
a stepwise order. Once inside the vector, the construct had to be transfected into BA/F3 cells. 
To study single point mutations some of the relevant point mutations were supposed to be 
subcloned into the Bcr-Abl construct and expressed in BA/F3 cells. 
 
To monitor the transfection and selection strategy with the pMACS 4-IRES.II vector and the 
BA/F3 cells, a pilot study was performed. A GFP gene was cloned into the pMACS 4-IRES.II 
vector and transfected into the BA/F3 cells. Expressed GFP will make fluorescent light that 
can be observed in a microscope.  
 
In conclusion, the cloning of this long Bcr-Abl gene proved to be more difficult than 
expected. First, misannealing resulted in an incomplete PCR product, which forced us to 
develop another strategy for this fragment. The 5’ part and the 3’part of Bcr-Abl was then 
successfully cloned in two vectors. However, all attempts to try to join the different Bcr-Abl 






1.1 The Philadelphia chromosome 
Important cellular functions like cell cycling are tightly controlled by multiple regulatory 
mechanisms. In cancer disease multiple genetic events are needed to destroy the network of 
cellular control mechanisms [Hanahan and Weinberg 2000]. After intensive studies of those 
events, many proteins playing major roles in cancer disease have been identified. In an 
increasing number of diseases this knowledge has lead to development of drugs targeting 
proteins that are believed to represent the real cause of cancer disease. Chronic myelogenous 
leukemia was the first malignancy shown to be associated with a specific cytogenetic lesion, 
the Philadelphia chromosomal translocation [Kabarowski and Witte 2000]. The Philadelphia 
chromosome was discovered in Philadelphia in 1960 [Nowell and Hungerford 1960]. It took 
13 years before J Rowley found that the Philadelphia chromosome results from a reciprocal 
translocation between the long arms of chromosome 9 and 22 [Rowley 1973]. Another 10 
years went before it was shown that the proto-oncogene Abl, normally found on chromosome 
9, was translocated to the Philadelphia chromosome in CML cells [Bartram et al. 1983]. We 
now know that the most important consequence of the Philadelphia chromosome consists in 
the fusion of the Bcr gene to the tyrosine kinase Abl, encoding the constitutive active fusion 








Figure 1.  A. On the cytogenetic level a minute chromosome can be found in more than 90 percent of 
patients with CML, which results from a translocation between chromosome 9 and 22, B. giving rise 
to a new cancer specific fusion chromosome stretching Bcr and Abl sequences on chromosome 22+. 
C. The resulting mRNA consists of Bcr fragments (usually exon 1 to 14) and Abl sequences (usually 
exon 2 until 11). D. The fusion protein Bcr-Abl exerts constitutive active tyrosine kinase activity. [For 







1.2 Chronic myelogenous leukemia 
Chronic myelogenous leukaemia is a monoclonal hematopoetic stem cell disorder 
characterised by an increase of leukocytes and their ancestors in the peripheral blood 
[Sawyers 1999]. Clinically, the primary symptoms can be moderate, but most patients 
complain about fatigue. Usually the spleen is enlarged at diagnosis. Typically, one will find 
immature bone marrow cells like myelocytes and metamyelocytes in the blood smear.  
The diagnosis is finally confirmed by detection of the characteristic translocation t(9;22) by 
assessment of bone marrow metaphases, detection of a fusion signal by FISH or the 
amplification of the Bcr-Abl transcript  by PCR [Hjort-Hansen et al. 2004].  
Over ninety percent of cases of chronic myelogenous leukemia are associated with the 
presence of the Philadelphia chromosome. 
 
 
Initially, CML is a slowly progressive disease with symptoms that usually develop gradually 
[Druker et al. 2001]. The disease progresses through three distinct clinical phases - chronic 
and accelerated phase and blast crisis, during which the leukemic clone progressively loses its 
ability to differentiate [Druker et al. 2001]. The chronic phase is characterized by 
accumulation of myeloid precursors and mature cells in bone marrow, peripheral blood and 
extramedullary sites [Calabretta and Perrotti 2004]. Most patients are diagnosed in the chronic 
phase. During the chronic phase of the disease, there is massive clonal expansion of myeloid 
cells, which retain the ability to differentiate [Druker et al. 2001]. This phase can last for 
several years before symptoms and signs of more aggressive disease appear, the so-called 
accelerated phase. In the accelerated phase the control of the proliferation becomes much 
more difficult. Counts rise to high levels, and the risk for tissue infiltration by white blood 
cells are present [Hillmann 1994]. 
 
As the disease progress, the number of blasts in the bone marrow and peripheral blood 
continues to increase, and the accelerated phase will evolve to an aggressive acute leukemia, 
referred to as a blast crisis [Hillmann 1994]. 
In two thirds of patients the blasts are myeloid, and in one third they are lymphoid [Druker et 





Untreated the disease is fatal after a variable period of time. Until the late nineties interferon 
in combination with cytosar, a cytostatic, has been the treatment of choice. Patients survived 
5-6 years in average during this treatment [Guilhot et al. 1997]. They usually died after a 
transformation from a chronic phase to accelerated phase or blast crisis, a terminal disease 
stage very similar to acute leukaemia [Sawyers 1999; Azam et al. 2003].  
Transition to blast crisis is the unavoidable outcome of CML except of patients receiving 
allogenic bone marrow transplantation early in the chronic phase [Calabretta and Perrotti 
2004]. Allogenic bone marrow or stem cell transplantation is still the only treatment known to 
cure CML. This approach is available only to patients who have a suitable donor and who are 
young enough to tolerate the procedure and the subsequent toxic effect of allogenic transplant 
[Herfindal and Gourley 2000]. The goal of therapy for CML in the chronic phase is to prolong 
survival and minimize symptoms by achieving complete hematologic response and a 
complete cytogenetic response [Herfindal and Gourley 2000].  
 
 
1.3 The Bcr-Abl protein 
On the protein level the reciprocal translocation of chromosomes 9 and 22 creates a cancer 
cell specific fusion protein (Bcr-Abl). It has recently been shown that the amino terminal abl 
sequences are important for auto inhibition of Abl. In case of the Bcr-Abl protein these 
sequences are replaced by fragments of the Bcr gene resulting in a constitutive active tyrosine 
kinase [Azam et al. 2003]. In contrast to other receptor tyrosine kinases Abl is located in the 
cytosol. It contains several domains that are important for cellular interaction. As a 
consequence, Abl activates multiple signal transduction pathways leading to uncontrolled cell 
growth, proliferation and apoptosis (reviewed by Sawyers 1999).   
 
 
1.4 Imatinib, a targeted drug for inhibition of Abl 
From the early nineties it was known that tyrosine kinases play a major role in development 
of cancer disease [Ullrich and Schlessinger 1990]. Tyrosine kinases are enzymes that transfer 
phosphate from ATP to tyrosine residues on substrate proteins that in turn regulate different 
cellular processes. Substances inhibiting tyrosine kinases were therefore systematically 
screened for their activity in cancer. STI 571, later called imatinib or Glivec (Novartis), was 




2002], (see Figure 2A). Initially, Imatinib was developed as a specific platelet derived growth 
factor receptor (PDGFR) inhibitor, but was also found to be a potent and selective inhibitor 
for Abl tyrosine kinases, including Bcr-Abl, as well as for c-kit and ARG [Mauro and Druker 
2001]. 
  
Due to its small size imatinib binds to the ATP binding pocket of the inactive form of the Abl 
kinase domain of Bcr-Abl (see Figure 2B). By preventing ATP from binding the 
phosphorylation of downstream substrates is disrupted. Signal pathways constitutively 
activated in CML cells are again shut down. Initial clinical studies demonstrated that imatinib 
treatment clearly induced a cytogenetic response in substantially more patients than standard 
treatment. Imatinib was, therefore rapidly drawn through the registration process [Capdeville 










Figure 2 Imatinib (STI571) is a small tyrosine kinase inhibiting molecule binding the ATP 
binding pocket of Bcr-Abl. A. A sketch showing the molecular formula of the tyrosine kinase 
inhibitor STI571, later called imatinib (Glivec) for the treatment of chronic myelogenous leukemia. 
Imatinib belongs to a class of compounds known as the 2-phenylaminopyrimidines, and is a small 
molecule not unlike the structure of ATP. B. Schematic representation of the mechanism of action of 
imatinib. The Bcr-Abl tyrosine kinase is a constitutively active kinase that functions by binding ATP 
and transferring phosphate from ATP to tyrosine residues on various substrates. This causes the excess 
proliferation of myeloid cells characteristic of CML. Imatinib functions by blocking the binding of 
ATP to the Bcr-Abl tyrosine kinase, inhibiting its activity. In the absence of tyrosine kinase activity, 
substrates required for Bcr-Abl function cannot be phosphorylated and subsequent cellular events are 
abrogated. From reference [Mauro and Druker 2001]. 
 
 
1.5 Imatinib resistance 
In 2001 Mercedes Gorre and co-workers [Gorre et al. 2001] introduced a novel mechanism of 
resistance to imatinib after molecular analysis of 11 imatinib resistant, advanced phase 
patients. In 8 of these 11 subjects an identical A>T point mutation was identified in the Abl 
kinase domain, resulting in a substitution of threonin in position 315 by isoleucin (T315I) 




pointing out that Bcr-Abl represents the driving oncogene also in these advanced phase 
patients 
 
Over 40 different mutations in the Abl kinase domain have since been identified in imatinib 
resistant patients inducing substitutions of 17 different amino acid residues [Martinelli et al. 
2005]. These residues are clustered within the Abl kinase domain (see Figure 3A). The most 
important locations concern the phosphate binding loop (amino acid position 248 to 255), 
residues around position 315 and the activation loop (position 350 to 400). Some residues like 
the T315 exert a very intimate contact to imatinib in the ATP binding pocket; whereas other 
residues are located far from the binding pocket and will not have any contact with imatinib 
(see Figure 3B). The latter group of mutations represents the majority of mutations identified 
in imatinib resistant patients.  
In conclusion, in the majority of patients developing resistance to imatinib we will find a Bcr-
Abl cell clone containing mutations in the kinase domain. These mutations will distort 
imatinib binding by sterical hindrance, or by trapping Abl in a conformation imatinib will not 
bind to. The majority of the more than 40 different mutations described in resistant patients 
belong to the second group. Therefore, given that imatinib exclusively binds to the inactive 
conformation of Abl, this might represent a major pitfall for the drug since it opens the 
possibility for resistance. This observation has also been important for the targeted 
development of second-generation tyrosine kinase inhibitors in CML, because drugs binding 
the active conformation of Abl could represent a choice in order to overcome resistance to 
imatinib. This idea directed the focus on combined src/abl inhibitors that were supposed to 
bind active conformation abl since this conformation is very close to Src. Multiple substances 
have been screened by several groups and at least three drugs are on their way into clinical 
practice. Dasatinib (Bristol-Myers Squibb) has almost reached registration after its superior 
effect on mutated Bcr-Abl has been shown both in vitro and in vivo [Shah et al. 2002]. In this 
respect we will in the future be faced with several drugs targeting Bcr-Abl. These drugs will 
be used sequentially on the basis of their resistance profile or a priori as a combination 






A.             B.  
 
Figure 3. Different point mutations in the Abl kinase domain prevent imatinib from binding in 
the ATP binding pocket. A. A sketch of the Abl kinase domain showing where in Bcr-Abl the 
different point mutations have been identified. The most important mutations are found in the p-loop, 
in residues around position 315 and in the activation loop. These point mutations altering the 
conformation of the ATP-binding pocket such that imatinib no longer can bind. B Imatinib bound to 
the ATP-binding site on Bcr-Abl. [Daub et al. 2004]. 
 
 
1.6 DNA cloning 
Techniques for DNA cloning have opened incredible opportunities to identify or study the 
genes involved in almost every known biological process [Herfindal and Gourley 2000]. DNA 
cloning is the basis for other related technologies, such as gene therapy and genetic 
engineering of organisms. DNA cloning also made it possible to do genome sequencing. 
 
DNA cloning is a technique for isolating and reproducing a large numbers of identical DNA 
fragments. By introducing recombinant DNA into host cells the foreign DNA is reproduced 





Cloning of DNA molecules from genome can be achieved by two different approaches: Cell 
based cloning or using polymerase chain reaction (see 3.2.9) [Passarge 2001]. For both these 
methods the use of restriction enzymes plays an important part. 
 
Restriction enzymes recognize a specific sequence on a DNA strand and cleave the DNA by 
catalyzing breaks in specific phosphodiester bonds [Trun and Trempy 2003]. The cleavage is 
on both strands of the DNA so that a double stranded break is made [Trun and Trempy 2003]. 
This cleavage can give two types of ends, depending upon the specific restriction enzyme. 
Some restriction enzymes make sticky ends, with protruding single strands, which form 
hydrogen-bonded base pair with complementary sticky ends of other DNA fragments cut with 
the same enzyme. Other restriction enzymes make blunt ends; cleave both strands of DNA at 
the opposing phosphodiester bonds, leaving no unpaired bases on either end [Nelson and Cox 
2002]. Any blunt end can be joined to any other blunt end regardless of how the blunt end was 
generated [Trun and Trempy 2003].  
 
The restriction enzymes were discovered in bacteria in the late 1960s [Campbell et al. 1999]. 
Bacteria use restriction enzymes as protection against intruding DNA from other organisms, 
such as viruses and other bacterial cells [Campbell et al. 1999]. There are three classes of 
restriction enzymes, indicated I, II and III. Type I and III cleave the recognition sequence 
unspecific and at random sites. Type II restriction enzymes, the type most used within the 
gene technology, is specific and cleave the DNA within the recognition sequence itself 
[Nelson and Cox 2002]. The DNA sequence recognized by Type II restriction enzymes is 
symmetric and usually palindromic. The DNA sequence is between 4 and 8 bp in length, with 
most restriction enzymes recognizing 4 or 6 bp [Trun and Trempy 2003]. 
When the plasmid vector and the DNA fragments to be cloned are cut with the same 
restriction enzymes, the DNA fragments can be ligated into the plasmid vector and form a 
circular recombinant DNA molecule (see 3.2.4). During the ligation reaction DNA ligase 
form phosphodiester bonds between the 3’hydroxyl and the 5’ phosphate ends of the nucleic 
acid molecule [Sambrook and Russell 2001].  
Cell based DNA cloning involves separating a specific gene or DNA fragment from a larger 
chromosome using restriction enzymes (see 3.2.1). In order to clone a gene, its DNA 
sequence needs a carrier that can take it into the cell. There are many different kinds of 
vectors and most of them are isolated from larger plasmids that occur naturally in bacterial 




DNA that can replicate separately from the host chromosome. Generally, a cloning vector 
contains three elements: a cloning site where the foreign DNA fragment can be inserted, a 
gene for antibiotics resistance and a replication origin to allow the plasmid to be replicated in 
the host cell.  
 
When cloning DNA segments amplified by PCR into plasmid vectors there are different ways 
to do this. One possibility is to introduce specific PCR primers modified at their 5’ ends so 
that they contain a suitable recognition site for restriction enzymes. By doing this the 
amplified DNA fragment of interest will carry restriction sites at its termini that can be used 
for further cloning into plasmid vectors. The vector and the amplified DNA fragment can thus 
be cleaved with appropriate restriction enzymes and ligated together [Sambrook and Russell 
2001] (see Figure 4).  
 
Another method is TA cloning (see 3.2.12) a much more efficient cloning strategy than blunt-
ended ligation and useful when compatible restriction sites are not available for subcloning 
DNA fragments from one vector into another. By using Taq polymerase, single 
deoxyadenosine is added to the 3’ ends of the PCR fragments. This can be exploited by 
cloning the PCR product into linearized T vector, fitted with single overhanging 3’ 
deoxythymidine residues at each of its 3’termini. PCR fragments that carry unpaired 
deoxyadenosin residues at their 3’termini can easily be cloned into vectors with single 
unpaired deoxythymidine residues at its 3’termini [Sambrook and Russell 2001], a fact that 
several commercial companies have taken advantage of. 
The recombinant DNA generated by PCR or cell based cloning is then transformed into 
suitable host cells and reproduced along with the host cell DNA. Bacteria are most often used 
as host cells, and strains of Escherichia coli (E. coli) cells are the most common cell to use 
because they are easy to transform with DNA plasmid [Sambrook and Russell 2001] and its 
metabolism are well understood [Nelson and Cox 2002]. To be able to take up foreign DNA, 
the bacteria cells need to be made competent. This is often achieved by treating them with 
divalent cations under cold conditions. 
For E. coli transformation with plasmid the DNA needs assistance to pass through the cell 
membranes and to reach the site where it can be expressed and replicated. The plasmids can 





Chemical transformation involves a short heat shock of the solution to induce the cells to take 
up the DNA. In electroporation a brief electrical pulse is applied to the solution containing the 
cells and the DNA fragments to be inserted. In both cases the intention is to simplify the 
penetration through the cell membranes.  
 
When recombinant DNA is transferred into bacterial cells (see 3.2.5) the recombinant DNA 
replicate independently of the cells genome. The host cells transformed by recombinant DNA 
are grown in culture and as the bacterium grows, the new recombinant DNA molecule is 
copied by DNA replication and, as the cell divides, the number of cells carrying the 
recombinant molecule increases [McPherson and Møller 2000]. 
 
To distinguish bacteria transformed by recombinant plasmids from bacteria that have no 
recombinant plasmid different methods have been developed. One way to do this selection is 
to use vectors carrying genes for antibiotic resistance. Most plasmid vectors contain antibiotic 
resistance gene that will change the antibiotic resistant of the bacteria when a fragment is 
transformed. This allows selection for recombinant plasmids because only those bacteria that 
have been successfully transformed with the desired recombinant plasmid molecules will 
grow on agar plates in the presence of that bacterium.  
 
To select for clones that have insert in their vectors a so-called blue-white screening can be 
done (see 3.2.15). This is a non-destructive histochemical procedure to detect β-galactosidase 
activity in transformed bacteria [Sambrook and Russell 2001]. However, this requires the use 
of plasmid vectors that carry unique restriction sites that serve as a marker with a marker 
gene. When DNA fragments are incorporated these marker genes are disrupted [Passarge 
2001].  
Using α–complementation (blue-white selection), the β-galactosidase enzyme will not be 
produced when the lacZ gene in the plasmid vector is disrupted, but a plasmid without an 
insert will still produce β-galactosidase because the lacZ gene is still intact [Passarge 2001]. 
β-Galactosidase cleaves a synthetic sugar, X-gal, that is similar to lactose, into two sugar 
components, galactose and glucose [Nelson and Cox 2002], one of which is blue [Passarge 
2001]. Therefore, colonies containing plasmid vectors without insert will turn blue; on the 





To identify clones carrying the recombinant plasmid, with the desired DNA insert, colonies 
are picked and grown in culture containing the appropriate antibiotic. The plasmid DNA is 
extracted by the standard minipreparation (see 3.2.7) technique and analysed by restriction 
digest. The size of the insert or the orientation of the insert can be verified by restriction 
analysis of minipreps of vector DNA. After digesting the DNA, the samples are run on a 0,7 
% agarose gel (see 3.2.2) and the band sizes formed are compared with DNA fragments of 
known size. To confirm that the cloned DNA fragments are correct sequencing need to be 
done. This is especially important when the cloned DNA fragment is generated by PCR, since 

































Figure 4. The different methods used when cloning a DNA fragment into a plasmid. 
DNA cloning involves separating a specific gene from a larger chromosome and incorporating it to a 
plasmid vector, before the recombinant DNA is transformed into host cells. The host cells transformed 
by recombinant DNA are grown in culture and the recombinant DNA molecule is replicated and 
reproduced along with the host cell DNA. Then the cells is plated onto agar plates containing the 
appropriate antibiotic. To identify clones carrying the recombinant plasmid, with the desired DNA 
insert, colonies are picked and grown in culture containing the appropriate antibiotic before the 






2 AIM OF THE STUDY 
 
The main purpose of this thesis is to develop an experimental system where the molecular and 
biological effects of the Glivec-resistant mutations in Bcr-Abl can be studied. 
 
To do this several sub-goals has to be achieved: 
 
• Cloning of GFP into the pMACS 4-IRES.II expression vector to test the transfection 
and selection of mouse BA/F3 cells. 
 
• Cloning of Bcr-Abl into a modified pBluescript vector for later use in easy transfer of 
Glivec-resistant mutations. 
 
• Cloning of Bcr-Abl from the modified pBluescript vector into the pMACS 4-IRES.II 









3.1.1 The reagents used in the different methods 
 
Used in method 3.2.1 
Enzyme Recognition 
sequence 
Buffer BSA  
2 % 
Manufacturer 
EcoRI  G/AATTC *10 X TA, Neb 4 
and  
Neb EcoRI 




10 X TA, Neb 2, 
Neb 4 and  
Neb EcoRI 
+ New England Biolabs 
 
FseI GGCCGG/CC Neb 4 + New England Biolabs 
 
KpnI GGTAC/C 10 X TA - Promega 
 
NdeI   CA/TATG 10 X TA - New England Biolabs 
 
NheI  G/CTAGC 10 X TA - New England Biolabs 
 
SacI GAGCT/C Neb 2 and Neb 4 + New England Biolabs 
 
*330 mM Tris acetate (pH 7.9), 660 mM KoAc, 100 mM Mg(OAc)2 
 
 
Generate blunt ends 
T4 DNA polymerase  New England Biolabs 
2mM dNTP  Takara 
 
Dephosphorylation 






Used in method 3.2.2 
Reagents  Specifications Manufacturer 
Agarose SeaKem® LE Agarose Cambrex 
10X TBE buffer 108 g Tris-base 
55 g boronic acid 
40 ml 0,5 M EDTA (pH 8.0) 
Add dH2O up to 1 liter 
 
Ethidium bromide  10 mg/ml GIBCO BRL® 
6 x Loading buffer 0,25 % bromphenole blue 
60mM Na2EDTA (pH 8.0) 
0,6 % SDS 
40 % (w/v) sucrose in water 
 
1 kb DNA ladder 1 part 1 μg/ml ladder 
24 parts TE-buffer 
5 parts 6 X T 
Invitrogen 
1 kb plus DNA ladder 1 part 1 μg/ml ladder 
24 parts TE-buffer 




Used in method 3.2.3 
Reagents  Specifications Producer information 
QIAquick Gel Extraction Kit Catalogue no. 28704 QIAgen 
Buffer QG From kit (Solubilization 
buffer) 
QIAgen 
Isopropanol  Increase the yield Arcus AS 
Buffer PE From kit (Wash buffer added 
ethanol) 
QIAgen 
Buffer EB From kit (Elution buffer) QIAgen 
 
 
Used in method 3.2.4 
Reagents  Specifications Manufacturer 
5 X ligation buffer 150 mM 1 M Trios (pH 7.6) 
25 mM 1 M MgCl2 
2,5 mM 0,1 ATP 
50 mM 1 M DTT 
24 % 40 % PEG (8000) 
50μg/ml 10 mg/ml BSA 
add dH2O up to 1000 ml 
 






Used in method 3.2.5 
Reagents  Specifications Manufacturer 
E. coli DH5α competent 
bacterial cells 
Genotype: DH5á™-T1R:  
F-ö80lacZ.M15 .(lacZYA-
argF)U169 recA1 endA 
1hsdR17(rk-, mk+) phoA  
SupE44 thi-1 gyrA96 relA1 
tonA 
Invitrogen Life Technologies 
SOC 20 g/l bacto-tryptone 
5 g/l bacto yeast extract 
8,6 mM NaCl 
2,5 mM KCl 
20 mM glucose 




Used in method 3.2.6 
Reagents  Specifications Manufacturer 
Buffer P1 From kit (resuspension buffer 
added RNase A) 
QIAgen 
Buffer P2  From kit (Lysis buffer) QIAgen 
BufferN3 From kit (Neutralization 
buffer) 
QIAgen 
Isopropanol  Arcus AS 
70 % ethanol  Arcus AS 
TE-buffer 10 mM TrisHCl (pH 8.0) 
1 mM EDTA 
H2O adjusted to a total 




Used in method 3.2.7 
Reagents  Specifications Producer information 
QIAprep Spin Miniprep Kit Catalogue no. 27106 QIAgen 
Buffer P1 From kit (resuspension buffer 
added RNase A) 
QIAgen 
Buffer P2  From kit (Lysis buffer) QIAgen 
BufferN3 From kit (Neutralization 
buffer) 
QIAgen 
Buffer PB From kit (Binding buffer) QIAgen 
Buffer PE From kit (Wash buffer) QIAgen 






Used in method 3.2.8 
Reagents  Specifications Manufacturer 
QIAgen Plasmid Midi Kit Catalogue no. 12145 QIAgen 
Buffer P1 From kit (resuspension buffer 
added RNase A) 
QIAgen 
Buffer P2  From kit (Lysis buffer) QIAgen 
Buffer P3 From kit (Neutralization 
buffer) 
QIAgen 
Buffer QBT Equilibration buffer QIAgen 
Buffer QC From kit (Wash buffer) QIAgen 
Buffer QF From kit (Elution buffer) QIAgen 
Isopropanol Precipitation Arcus AS 
70% ethanol Wash Arcus AS 
TE-buffer 10 mM TrisHCl (pH 8.0) 
1 mM EDTA 
H2O adjusted to a total 






Reagents  Specifications 
LB medium with 50 μg/ml  
ampicillin or kanamysin 
10 g/l bacto-tryptone 
5 g/l bacto-yeast extract 
171 mM NaCl 
50 μg/ml with the appropriate antibiotic 




Used in method 3.2.9 
Reagents  Specifications Manufacturer 
Elongase 5X Buffer A  Invitrogen 
Elongase 5X Buffer B  Invitrogen 
XL Control PCR Template 25 ng/μl in TE Buffer Invitrogen 
XL Control PCR Primer 0,2 ng/μl in TE Buffer Invitrogen 
50 mM dNTP Mix 12,5 mM dATP 
12,5 mM dCTP 
12,5 mM dGTP 
12,5 mM dTTP 
neutralized at pH 8.0 in water 
Invitrogen 
Sterile water From kit Invitrogen 






Used in method 3.2.10 




























Used in method 3.2.11 
Reagents  Specifications Manufacturer 
Agarose Sea®Kem LE Agarose Cambrex 
1X TAE buffer   
Crystal Violet Solution  2 mg/ml Invitrogen 
6X Crystal Violet Loading 
Buffer 
30 % Glycerol 
20 mM EDTA 
100 μg/ml Crystal Violet 
Invitrogen 
Excising 
6,6 M Sodium iodide 6,6 M Sodium iodide 
16 mM Sodium sulfite 
Invitrogen 
Binding Buffer 7 M Guanidinium HCl Invitrogen 
Isolating 
1X Final Wash 100 mM NaCl  Invitrogen 
TE-buffer 10 mM TrisHCl (pH 8.0) 
1 mM EDTA 








Used in method 3.2.12 
Reagents  Specifications Manufacturer 
TOPO®XL PCR Cloning Kit Catalogue no. K4700-10 Invitrogen 
pCR®-XL-TOPO vector 10 ng/μl plasmid DNA in: 
50 % glycerol 
50 mM Tris-HCl (pH 7.4) 
1 mM EDTA 
2 mM DTT 
0,1% Triton X-100 
100 μg/ml BSA 
Phenol red 
Invitrogen 
6X TOPO® Cloning Stop 
Solution 
0,3 M NaCl 
0,06 M MgCl2 
Invitrogen 
One Shot® TOP10 
Electrocompetent E. coli 
Catalogue no. 4040-50 Invitrogen 
SOC 20 g/l bacto-tryptone 
5 g/l bacto yeast extract 
8,6 mM NaCl 
2,5 mM KCl 
20 mM glucose 




Used in method 3.2.13 
Reagents  Specifications Manufacturer 
sodiumacetat  (NaOAc) 3 M, pH 5,2  
100 % ethanol  Arcus AS 
70 % ethanol  Arcus AS 
Big Dye version 3.1  Applied Biosystem 
Primer T7, T6, T3, CMV FW 10mM Operon 
5x Sequencing buffer 400 mM TrisHCl 
10 mM MgCl2 
pH adjusted to 9.0 
 
EDTA 125 mM 
23,3g diNaethylene-
diaminetetraacetic * 2 H2O 





Used in method 3.2.15 
Reagents  Specifications Manufacturer 
X-Gal  50mg/ml Promega   






Used in method 3.2.16 
Reagents Specifications 
50 % glycerol  
 
Used in method 3.2.17 and 3.2.18 
Reagents  Specifications Manufacturer 
BA/F3 cells Mouse pro B cell  
DSMZ  no.: ACC 300 
Depositor:  
Obtained from RIKEN Cell 
Bank (RCB0805), Tsubuka 
Science City, Ibaraki, Japan 
Growth medium 90 % RPMI 1640 
10 % FBS 
100 μl (10 μg/ml) IL-3 
 
Opti-MEM®  GIBCO™,  





3.1.2 The two DNA ladders 
 





3.1.3 Plasmid constructs used in this thesis 
 
 




















3.2.1 Digestion of DNA with restriction enzymes  
In separate tubes, the plasmid vector and the DNA were digested with the appropriate 
restriction enzyme(s). 
 
In a microfuge tube, the following mixture was set up for each digesting reaction: 
DNA (1-2 μg)    x μl  
10x restriction enzyme buffer  2 μl  
Restriction enzyme(s)           0,5 μl 
dH2O to a final volume of               20 μl  
 
A control reaction was set up containing all the reagents listed above except the restriction 
enzyme(s). 
The reaction was performed in microfuge tubes at 37°C for 1-2 hours.  
 
When digestion was completed 4 μl 6 x Gel loading buffer was added to the reaction. 
 
To generate blunt ends 
If it is not possible to make complementary sticky ends, making blunt ends is an alternative. 
These ends can be joined to any other blunt end regardless of how the blunt end was 
generated. Blunt-end cloning is inefficient and blunt ligation gives no occasion to affect the 
orientation of the DNA fragment within the vector. 
 
T4 DNA polymerase convert protruding 3’ ends to blunt ends in the presence of high 
concentrations of dNTPs. Protruding 3’ends are removed from double-stranded DNA by 
3’→5’ exonuclease activity of bacteriophage T4 DNA polymerase [Sambrook and Russell 
2001]. 
 
After 1,5 hours at 37°C the reaction was added: 
T4 DNA polymerase   1 μl  





Thereafter the reaction was incubated at 37 °C for 20 minutes, then 20 minutes at 70 °C to 
inactivate the DNA polymerase.  
Next the appropriate restriction enzyme that generates the second end was added.  
Lastly, the reaction was incubated at 37 °C for 1,5 hours.  
When digestion was completed 6 x Gel loading buffer was added (4 μl for the 20 μl reaction 
volume).  
 
Dephosphorylation of plasmid vectors with alkaline phosphatase 
To prevent self-ligation of plasmid vectors in ligation reaction the terminal 5’-phosphate 
groups may be removed. Using alkaline phosphatase, the terminal 5’-phosphate residues from 
single- or double stranded DNA or RNA will be removed. This dephosphorylation reaction 
suppresses self-ligation of vector molecules and will decrease the number of “empty” vectors. 
A foreign DNA with intact 5’-terminal phosphate residues can be ligated efficiently into the 
dephosphorylated plasmid DNA. Shrimp alkaline phosphatase (SAP) is isolated from arctic 
shrimp and is one of the most widely used phosphatases in molecular cloning [Sambrook and 
Russell 2001].  
 
Closed circular plasmid DNA was digested with the desired restriction enzyme as described 
above for 1,5 hours at 37°C. 
Thereafter 1 μl of 10 x SAP buffer was added to the linearized plasmid and incubated for 
another 30 minutes at 37°C before the digestion was completed and 4 μl 6 x Gel loading 
buffer was added to the reaction.  
 
3.2.2 Agarose gel electrophoresis 
Agarose gel electrophoresis is a method used to separate and identify DNA on the basis of 
their size and rate of movement through a gel under the influence of an electric field. Since 
the nucleic acids are negatively charged due to the negatively charged phosphate group, they 
will migrate to the positively charged electrode (anode). Distinct bands, based on the 
molecule size, will form on the gel. Shorter DNA molecules will move faster than longer, 
since they are able to slip through the matrix more easily. The band can be visualized by 




light. Ethidium bromide is a ring-formed structure that intercalates between the base pairs in 
the DNA double helix. It is a mutagen and was handled with care. 
 
Preparing the gel 
1. A 0,7% agarose gel was made by mixing 0,7 g agarose with 90 ml distilled water and 10 ml 
10X TBE buffer. 
 
2. The mixture was heated in a microwave oven until all agarose had melted and the solution 
had started to boil.  
 
3. The gel solution was then left to cool (to approximately 65 °C). 
 
4. 10 μl of ethidium bromide were added after the mixture had cooled, and gently mixed into 
the agar.  
 
5. The gel was poured slowly into a gel rack, the comb was set at one side of the gel, and any 
bubbles in the solution removed. The gel was allowed to set (20 to 30 minutes). 
 
6. After 20 minutes, when the gel had solidified, the comb was removed, and the gel, together 
with the rack, was soaked into a chamber with 1X TBE gel running buffer. The gel was 
placed with the wells facing the electrode that provide the negative current (cathode).  
 
Loading and running the gel 
Loading buffers were added to the DNA samples in order to visualize it and sediment it the 
gel wells (6 X T, added at the end of the cutting). 
 
1. A DNA ladder, a mixture of DNA fragments of known size, was loaded into the first well. 
This was used to determine the absolute size of the separated DNA strand by comparing their 
migration with that of the ladder (see Figure 5).  
 
2. The samples were loaded into the wells and the lid of the electrophoresis chamber was 






3. The ethidium bromide stained gel was visualised under UV light and photographed. 
Eventually the required DNA band was cut out and a QIAquick Gel Extraction was done (see 
3.2.3). 
 
3.2.3  QIAquick Gel Extraction Kit 
Bands cut from an agarose gel were purified from the gel matrix using QIAquick Gel 
Extraction Kit. 
 
1. The required DNA fragment was excised from the agarose gel using a scalpel and 
transferred to a microcentrifuge tube. 
 
2. The size of the gel slice was determined by weight and 3 volumes of Buffer QG were added 
to 1 volume of gel (100 mg ≈100 μl). 
 
3. The tube was incubated at 50°C until the gel slice had dissolved completely. To help 
dissolve the gel, the tube was mixed by vortexing several times during the incubation.  
 
4. After the gel slice had dissolved, 1 gel volume of isopropanol was added to the sample and 
mixed. 
 
5. To bind DNA, the sample was applied to a QIAquick column, and centrifuged at 13000 
rpm for 1 minute in a Microcentrifuge, Mini Spin (eppendorf). 
 
6. The flow-through was discarded. 
 
7. To remove all traces of agarose, 0,5 ml Buffer QG was added to the column and 
centrifuged for 1 minute in a Microcentrifuge, Mini Spin (eppendorf). The flow-through was 
discarded.  
 
8. The column was washed by adding 0,75 ml Buffer PE and centrifuged for 1 minute in a 





9. The flow-through was discarded and the column was centrifuged for and additional minute 
in a Microcentrifuge, Mini Spin (eppendorf). 
 
10. The QIAprep spin column was placed in a clean 1,5 ml microcentrifuge tube and the DNA 
was eluted by adding 50 μl Buffer EB to the centre of the membrane before it was centrifuged 
for 1 minute in a Heraeus, Biofuge pico.  
 
3.2.4 DNA ligation 
Ligation is the process in which an insert are annealed into a vector by a covalent bond called 
phosphodiester bond. DNA ligases catalyze the end-to-end joining of the DNA by forming a 
phosphodiester bond between the 3’hydroxyl and the 5’phosphate ends of nucleic acid 
molecules [Sambrook and Russell 2001].  
 
When cutting with restriction enzymes a break is formed in the phosphodiester back bond. 
This nick, a broken phosphodiester bond leaving a free 3’ OH and a free 5’ phosphate, is 
sealed by DNA ligase [Nelson and Cox 2002].  
Ligation is an energy requiring reaction that occurs in three distinct steps [Trun and Trempy 
2003]. In the first step the adenyl group from ATP is covalently attached to ligase and 
inorganic phosphate is released. Next, the adenyl group is transferred from ligase to the 5’-
phosphate of the DNA in the nick. Lastly, the phosphodiester bond is formed when the 
3’hydroxyl end in the nick attacks the activated 5’phosphate. AMP is released in the process 
[Trun and Trempy 2003].  
 
The enzyme used to ligate DNA fragments is an enzyme from bacteriophage T4 called T4 
DNA ligase [Sambrook and Russell 2001]. This is a monomeric protein of 487 amino acids. 
 
 
In a microfuge tube, the following ligation mixture was set up: 
Plasmid vector  x μl 
DNA insert   x μl 
5 x ligation buffer   4 μl 
T4 DNA ligase  1 μl 





To do a self-ligation test, a control reaction containing all the reagents listed above except the 
DNA insert was set up. 
 
The ligation mixture was set to incubation overnight at 14°C. 
 
3.2.5 Transformation of DNA into competent E. coli DH5α cells 
Transformation is the introduction of a plasmid into a competent cell. A competent cell is a 
cell that is chemically treated to allow its membrane to be permeated by plasmids. The 
plasmid will be replicated in the bacteria, which will copy the DNA fragment of interest. 
Often the plasmid carries a gene that can make the bacteria resistant to an antibiotic. Only the 
bacteria that carry the plasmid will grow.  
 
All steps in this protocol were carried out as sterile as possible.  
 
1. Frozen competent E. coli DH5α cells were removed from the –80 °C freezer and thawed on 
ice at room temperature.   
 
2. The ligation mixture was diluted to100 μl with distilled water.  
 
3. 300 μl competent E. coli DH5α cells and 100 μl off the diluted ligation mix were dispensed 
into sterile falcon tubes chilled on ice.  
 
4. The tube was incubated on ice for 30 minutes 
 
5. The cells were heat shocked at 37°C for 2 minutes 
 
6. Immediately 5 ml of SOC. was added and the mixture was incubated at 37°C with vigorous 
shaking at 225 rpm for 45 minutes. 
 






8. The supernatant was poured off and the pellet was resuspended in the remaining 
supernatant (approximately 0,5 ml).  
 
9. 100 μl was transferred to the centre of an agar plate containing appropriate antibiotic, and a 
sterile spreader sealed in a flame was used to spread the solution over the entire surface of the 
plate.  
 
10. The plate was stored at room temperature until the liquid had been absorbed. 
 
11. The plate was inverted and incubated overnight at 37 °C. 
 
After an overnight incubation at 37 °C the numbers of antibiotic-resistant colonies were 
counted. The self-ligation test should yield few if any colonies, whereas the ligation mixture 
should yield increasing numbers of colonies containing recombinant plasmid molecules. 
 




Extraction of plasmids from bacterial cells 
Three different methods were used for preparation of plasmid DNA from E. coli, dependent 
on the requirement for quality and quantity. When purifying where of no importance the 
“Miniprep light method” was used. This method is a simple and relatively low cost variant 
where no column and fewer amounts of buffers are used. A variety of kits for plasmid 
purification are available from commercial vendors. The “QIAprep Spin Miniprep Kit” was 
chosen when the DNA was to be used in cloning or in the DNA sequencing process. For 
larger quantity where the quality of DNA was of importance the DNA was purified using the 
“QIAGEN Plasmid Midiprep”. This method yields DNA that is clean enough for transfection 





3.2.6 ”Miniprep light” 
1. 1,5 ml overnight culture of E. coli in LB medium was transferred to a microcentrifuge tube 
and centrifuged 30 seconds. The supernatant was discarded. 
 
2. The pelleted bacterial cells were resuspended in 100 μl Buffer P1 by vortexing. 
 
3. 100 μl Buffer P2 was added and mixed carefully. For 5 minutes the solution was incubated 
at room temperature.   
 
4. 140 μl Buffer N3 was added and mixed immediately, but thoroughly by inverting the tube. 
 
5. The tube was centrifuged for 10 minutes at 13000 rpm in a Microcentrifuge, Mini Spin 
(eppendorf). A compact white pellet formed. 
 
6. The supernatant from step 5 was applied to a new microcentrifuge tube. 
 
7. 350 μl of isopropanol was added and the tube was inverted.   
 
8. For 5 minutes the tube was incubated at room temperature. 
 
9. The tube was centrifuged for 10 minutes at 13000 rpm. The supernatant was discarded. 
 
10. The solution was washed by adding 400 μl of 70% ethanol 
 
11. The tube was centrifuged for 5 minutes at 13000 rpm in a Heraeus, Biofuge pico. The 
supernatant was discarded. 
 
12. The tube was air-dried for 20 minutes in room temperature. 
 





3.2.7  QIAprep Spin Miniprep Kit  
 
Isolation of plasmid DNA was performed using the QIAprep Spin Miniprep Kit. 
 
To screen the colonies for correct insert a selection of colonies from the transformation 
procedure was picked, by stabbing a sterile toothpick into the soft agar. The inoculums were 
transferred into tubes of LB medium containing the appropriate antibiotic before the tubes 
were incubated at 37°C with vigorous shaking overnight.  
Another starting point was overnight cultures started from freezing stocks. 
 
1. 1,5 ml overnight culture of E. coli in LB medium was transferred to a microcentrifuge tube 
and centrifuged 30 seconds at 13000rpm in a Microcentrifuge, Mini Spin (eppendorf). The 
supernatant was discarded. 
 
2. The pelleted bacterial cells were resuspended in 250 μl Buffer P1 by vortexing. 
 
3. 250 μl Buffer P2 (lysis buffer) was added and mixed carefully. The solution became 
viscous and slightly clear. For 5 minutes the solution was incubated at room temperature.   
 
4. 350 μl Buffer N3 (neutralization buffer) was added and mixed immediately, but thoroughly 
by inverting the tube. 
 
5. The solution was centrifuged for 10 minutes at 13000 rpm in a Heraeus, Biofuge pico. A 
compact white pellet formed. 
 
6. The supernatants from step 5 were applied to a QIAprep spin column by decanting and 
pipetting before it was centrifuged for 60 seconds in a Microcentrifuge, Mini Spin 
(eppendorf). The flow-through was discarded.  
 
7. The QIAprep spin column was washed by adding 0,5 ml Buffer PB and centrifuged for 60 





8. Further the QIAprep spin column was washed by adding 0,75 ml Buffer PE and centrifuged 
for 60 seconds in a Microcentrifuge, Mini Spin (eppendorf). 
 
9. The flow-through was discarded, and centrifuged for an additional minute in a 
Microcentrifuge, Mini Spin (eppendorf) to remove residual wash buffer. 
 
10. The QIAprep spin column was placed in a clean 1,5 ml microcentrifuge tube and the DNA 
was eluted from the QIAprep column with 50 μl Buffer EB by adding it to the centre of the 
membrane. The column was left for 1 minute, before it was centrifuged for 1 minute in a 
Heraeus, Biofuge pico.  
 
11. The DNA yield of the eluate was then determined using a spectrophotometer to measure 
absorbance at a wavelength of 260 nm 
 
3.2.8 QIAGEN Plasmid Midiprep 
Preparation of DNA plasmid for electroporation was performed using QIAGEN Plasmid Midi 
Kit. 
1. In a 500 ml volumetric flask 0,5 ml of overnight culture previously used for miniprep was 
diluted into 100 ml selective LB medium. The culture was grown at 37°C over night with 
vigorous shaking.  
 
2. The dilution was transferred to a centrifuge tube and the bacterial cells were harvested by 
centrifugation in a Sorvall RC 26 PLUS rotor in a SLA1500 centrifuge at 6250 rpm for 5 
minutes at 4°C.  
 
3. The supernatant was discarded. To remove all traces of supernatant the open centrifuge 
tube was set up side down on a paper until all medium had drained. 
 
4. The bacterial pellet was resuspended in 4 ml Buffer P1 by vortexing until no cell clumps 
remained. 
 
5. 4 ml of Buffer P2 was added and mixed carefully before it was incubated at room 




6. 4 ml of chilled Buffer P3 was added and mixed immediately but gently by inverting before 
it was incubated on ice for 15 minutes. 
 
7. The solution was centrifuged in a Sorvall RC 26 PLUS rotor in a SLA1500 centrifuge at 
11500 rpm for 30 minutes at 4°C. The supernatant containing plasmid DNA was removed by 
filtration. 
 
8. A QIAGEN-tip was equilibrated by applying 8 ml Buffer QBT, and the column was 
allowed to empty by gravity flow.  
 
9. The supernatant from step 7 was applied to the QIAGEN-tip and allowed to enter the resin 
by gravity. 
 
10. The QIAGEN-tip was washed with 2 x 10 ml Buffer QC. 
 
11. The DNA was eluted with 5 ml Buffer QF. The eluate was collected in a 10 ml tube.  
 
12. The DNA was precipitated by adding 3,5 ml room temperature isopropanol to the eluted 
DNA. The solution was mixed and centrifuged in a in a Sorvall RC 26 PLUS rotor in a SS-34 
centrifuge at 11200 rpm for 30 minutes at 4°C. The supernatant was carefully decanted. 
 
13. The DNA pellet was washed with 2 ml of room temperature 70% ethanol, and centrifuged 
in a Sorvall RC 26 PLUS rotor in a SS-34 centrifuge at 11200 rpm for 10 minutes at 4°C. The 
supernatant was carefully decanted, and the remaining liquid was sucked off without 
disturbing the pellet.  
 
14. The pellet was air-dried for 5-10 minutes, and the DNA was redissolved in 0,5 ml TE-
buffer.  
 
15. The DNA yield was then determined using a spectrophotometer to measure absorbance at 





3.2.9  Polymerase Chain Reaction (PCR) 
Polymerase chain reaction is a cell-free technique, which is used to amplify a specific DNA 
sequence. In an exponential manner a small amount of DNA is amplified into a large amount 
of DNA in a very short time [Passarge 2001]. 
 
In order to use PCR, one must know a part of the sequence on either side of the region of 
interest in DNA to be amplified, because the only DNA segment that can be amplified is the 
segment between the two primers [Nelson and Cox 2002].  
 
The DNA containing the sequence to be amplified is incubated in a test tube with the primers, 
each complementary to the ends of the targeted DNA, the four deoxynucleotides and a heat 
stable DNA polymerase.  
The heat stable Taq DNA polymerase, from the thermophilic bacterium Thermus aquaticus, is 
not inactivated at the high denaturation. 
 
The PCR process consists of a series of about 25-35 subsequent cycles. Each cycle consists of 
three precisely time-controlled and temperature-controlled steps – denaturation, annealing and 
extension.  
 
1) The first step separates the double stranded DNA into two single strands by use of a high 
temperature, usually 94-95°C, is used. This denaturing step breaks the hydrogen bonds 
between the two strands.  
 
2) Then the temperature is lowered to 55°C to allow the primers to base pair to their 
complementary sequences on the template strands.  
 
3) Further the reaction is heated to 72°C, the optimal temperature for the heat stable DNA 
polymerase to replicate the single stranded DNA segments. The DNA polymerase uses 
deoxynucleotides as building blocks of the new strands.  
 






4) Finally the reaction is cooled down to 4 °C where it can be stored until the user terminates 
the program [McPherson and Møller 2000].   
 
PCR is called a chain reaction because newly synthesized double-stranded DNA molecules 
are once again denatured and each single strand acts as a new template for further DNA 
synthesis [Passarge 2001].  
 
Karl B. Mullis invented PCR in 1983 [Nelson and Cox 2002] and in 1993 he won a Nobel 
Prize in Chemistry for developing this revolutionary technology. Today PCR has a major 
impact on biological and medical research and biotechnology. PCR is used for a variety of 
tasks, such as the detection of hereditary diseases, the identification of genetic fingerprints, 
and the diagnosis of infectious diseases, the cloning of genes, paternity testing, and DNA 
computing [Nelson and Cox 2002].  
 
3.2.10 Amplifying the Bcr-Abl gene using PCR 
The intention is to isolate and amplify the different fragments in the Bcr-Abl gene using PCR 
and different primers (see Table 1).  
 
Table 1.  Primers and templates used for amplification of the Bcr-Abl gene. 
Tube Fragment Primers Templats  
1. Control PCR product XL Control PCR Primer XL Control PCR templat 
2. Fragment A Bcr-*F(EcoRV) + SacI-*R Template (pEYKBA) 
3. Fragment B SacI-F + AatII-R Template (pEYKBA) 
4. Fragment C AatII-F + Abl-R Template (pEYKBA) 
5. Fragment BC SacI-F + Abl-R  Template (pEYKBA) 
6. Fragment ABC Bcr-F + Abl-R Template (pEYKBA) 
*F = Forward 





The following PCR reaction was set up (tube 1.): 
Elongase 5 X Buffer A  5 μl 
Elongase 5 X Buffer B  5 μl 
XL Control PCR Template   1 μl 
XL Control PCR Primers   1 μl 
50 mM dNTPs   0,5 μl 
Sterile Water to a final volume of  50 μl 
To each of the tubes (2-6) there was applied  
 
Elongase 5 X Buffer A  5 μl 
Elongase 5 X Buffer B  5 μl 
Plasmid Template (pEYKBA) 1 μl 
50 mM dNTPs   0,5 μl 
Primer F     1μl 
Primer R    1 μl 
Sterile Water to a final volume of   50 μl 
 
Table 2. The PCR program used to amplify the different fragments in the Bcr-Abl gene. 
Step Time  Temperature  Cycles 
1. Initial Denaturation 2 minutes 94°C 1X 
2. Denaturation 15 seconds 94°C 25X 
3. Annealing 1 minute 56°C 25X 
4. Extension 5 minutes  68°C *25X 
5. Final Extension 7 minutes 72°C 1X 
6. Storage For ever 4°C ∞ 
*Go to step 2. 24 times more 
1. The program was started and paused when the heat block reached 94°C.  
 
2. The tubes were placed on the block for 30 seconds before 1 μl of Elongase™ polymerase 
mix was added.  
 




3.2.11 Gel –purifying PCR products using crystal violet agarose gel 
In traditional ethidium bromide agarose gel electrophoresis the DNA is exposed to UV light 
and this may damage the DNA and decrease the cloning efficiency. To avoid damaging the 
PCR products agarose gel electrophoresis using crystal violet was chosen. Using this method 
the PCR products can be visualized under normal light as a thin blue band. PCR products can 
also be visualized while the gel is running and excised as soon as they are sufficiently 
resolved (TOPO® XL PCR Cloning Kit, Instruction manual).  
 
 
Preparing the gel 
1. A 0,8% agarose gel was made by using 0,4 g of agarose and 50 ml 1X TAE buffer in a 
volumetric flask.  
 
2. The mixture was placed in the microwave oven and heated until just boiling. The flask was 
swirled to dissolve the agarose and continued to heat until the agarose was dissolved and the 
nucleases destroyed.  
 
3. The agarose was cooled for a few minutes before 20μl 2mg/ml Violet solution Crystal was 
added.  
 
4. The gel was poured into a gel rack and the comb was set in the gel. 
 
5. After 20 minutes, when the gel had solidified, the gel, together with the rack was 
transferred to a chamber with 1X TAE buffer.  
 
6. The 1X TAE running buffer was made using 90 ml distilled water and 10 ml 10X TAE 
buffer. There should be enough running buffer to submerge the gel. 
 
 
Loading and running the gel 
1. 8 μl of 6X Crystal Violet Loading buffer was added to 40 μl of the PCR amplification 





2. The gel was run at 80 volts until a thin blue PCR product was visible on the gel. 
 
3. The PCR product was excised  
 
 
Excising the PCR Product 
1. The PCR product was excised from the gel using a scalpel and put into a microcentrifuge 
tube. 
 
2. The size of the gel slice was determined by weight and 2,5 volumes of 6.6 M sodium iodide 
was added to 1 volume of gel before it was mixed by vortexing. 
 
3. The tube was incubated at 42 to 50 °C until the gel slice had dissolved completely. To help 
dissolving the gel, the tube was vortexed several times during the incubation. 
 
4. The tube was placed at room temperature and 1,5 volume of Binding Buffer was added 
before the tube was mixed well.  
 
Isolating the PCR product 
1. The mixture from step 4 over was transferred into a S.N.A.P™ Purification column and 
centrifuged for 30 seconds at 13000 rpm in a Microcentrifuge, Mini Spin (eppendorf). 
 
2. The liquid in the collection vial was poured back onto the column and centrifuged for 
additional 30 seconds. This step was done twice, to bind the DNA to the column, before the 
supernatant was discarded. 
 
3. After the last centrifugation 400 μl of 1X Final Wash was added to the column and 
centrifuged 30 seconds at 13000 rpm in a Microcentrifuge, Mini Spin (eppendorf).  
 
4. Step 3 was repeated and the supernatant was discarded after the final centrifugation. 
 
5 To dry the column resin, the column was centrifuged at 13000 rpm speed for 1 minute 





6. The column was placed in a clean microcentrifuge tube and 40 μl of TE buffer was added 
directly to the column and incubated for 1 minute at room temperature. 
 
7. The column was centrifuged for 1 minute at 13000 rpm in the Microcentrifuge, Mini Spin 
(eppendorf) to elute the DNA into the microcentrifuge tube.  
 
8. The tube was placed on ice. 
  
3.2.12 Cloning of the BC-fragment into pCR®-XL-TOPO® vector 
TOPO®XL PCR Cloning is an efficient one-step cloning strategy for the cloning of long PCR 
products.  
 
1. A 5 μl TOPO®cloning reaction was set up in a microcentrifuge tube: 
Gel-purified PCR product  4 μl 
pCR®-XL-TOPO® vector  1 μl 
 
2. The reaction was mixed gently and incubated for 5 minutes. 
 
3. After 5 minutes incubation, 1 μl of the 6X TOPO® Cloning Stop Solution was added and 
mixed. 
 
4. The tube was briefly centrifuged and placed on ice. 
 
 
Chemical Transformation of TOPO® vector into One Shot® cells 
1. 2 μl of the TOPO®cloning reaction was added into a vial of One Shot® cells and mixed 
gently. 
 
2. The tube was incubated on ice for 30 minutes.  
 





4. The cell tube was transferred back on ice and incubated for 2 minutes. 
 
5. 250 μl of room temperature S. O. C. was added.  
 
6.  The tube was set at 37°C with vigorous shaking for 1 hour. After the incubation the tube 
was placed on ice.  
 
7. 100 μl was spread on a prewarmed kanamycin plate. 
 
8. The plate was incubated overnight at 37°C. 
 
 
The DNA sequencing process  
DNA sequencing, known as dideoxy sequencing, the Sanger method or chain termination 
method was developed by the British scientist Frederick Sanger in the1970s. 
The method is used to determine the exact nucleotide sequence in a given DNA fragment 
[Campbell et al. 1999].  
 
This technique utilizes 2’,3’-dideoxynucleotide triphosphates (ddNTPs), molecules that differ 
from deoxynucleotides (dNTPs) by lacking a hydrogen atom attached to the 3’ carbon rather 
than a hydroxyl group. These molecules will terminate the DNA chain elongation because 
they cannot form a phosphodiester bond with the next deoxynucleotide [Passarge 2001].  
 
During the sequencing reaction, when the temperature reach 94 °C, the DNA double helix is 
separated and the template strand is supplied with 
• DNA primers (complementary to the template which is to be sequenced) 
• DNA polymerase I (an enzyme that replicates DNA) 
• A mixture of all four normal deoxynucleotides (dATP, dGTP, dCTP and dTTP) in 
ample quantities. 
• A mixture of all four dideoxynucleotides (ddATP, ddGTP, ddCTP and ddTTP) in 






Because all four normal nucleotides are present, chain elongation proceeds normally until, by 
chance, DNA polymerase inserts a dideoxynucleotide instead of a normal deoxynucleotide. 
The competition between dideoxynucleotide and deoxynucleotide for incorporation into the 
growing chain will lead to a representation of lengths of DNA that correspond to the first 200-
500 residues complementary to the template.  
 
The tagged fragments are subsequently separated on a thin column. At the base of the column 
a laser is located. As the DNA fragments run off the column, they pass through the laser 
beam, fluoresce, and the wavelength of the fluorescence is recorded and sent to a computer. 
The order of the fluorescently tagged molecules coming off the column reflects the sequence 
of the template DNA [Nelson and Cox 2002]. 
 
Each of the four dideoxynucleotides fluoresces a different colour when illuminated by a laser 
beam and an automatic scanner provides a printout of the sequence [Nelson and Cox 2002]. 
 
3.2.13 DNA Sequencing 
Before sending samples for sequencing they were precipitated. The QIAgen minipreps were 
used: 
 
In a microcentrifuge tube 
5 μl 3M NaOAc (pH 5,2) 
150 μl 100% ethanol 
was added to 50 μl QIAgen purified DNA. 
 
1. The tube was vortexed and then centrifuged at 13000 rpm for 20 minutes at 4°C in a 
Heraeus Biofuge fresco centrifuge.  
 
2. The supernatant was sucked off. 
 
3. 0,5 ml 70% ethanol was added and the solution was centrifuged at 13000 rpm for 5 minutes 





4. The supernatant was sucked off. 
 
5. The sample was air-dried for 20-30 minutes. 
 
6. The DNA precipitate was resuspended in 50 μl of sterile water   
 
 




A sequencing PCR reaction was set up: 
DNA (about 500 ng) in sterile water  6 μl 
Big Dye version 3,1    2 μl 
Primer (10μM)    1 μl 
5 X sequencing buffer    3 μl 
Sterile water to a final volume of            20 μl 
 
 
Table 3.  PCR program for plasmid DNA sequencing 
Step Time  Temperature  Cycles 
1. Initial Denaturation 2 minutes 94°C 1X 
2. Denaturation 1 minute 94°C *35X 
3. Annealing 2 minutes 63°C 35X 
4. Replication 2 minutes 72°C 35X 
5. Final Extension  10 minutes 72°C 1X 
 ∞ 4°C - 







1. After the sequencing PCR the product was precipitated in a microcentrifuge tube as 
described below.  
125 mM EDTA  2 μl 
3 M NaOAc (pH 5,2)  2 μl 
50 μl 100% ethanol  50 μl 
Sequencing PCR product  20 μl 
 
2. The solution was mixed and incubated in room temperature for 15 minutes.  
 
3. The tube was centrifuged at 13000 rpm for 15 minutes in room temperature in a Heraeus, 
Biofuge pico. 
 
4. The supernatant was removed immediately  
 
5. 150 μl of 70% ethanol was used to wash the DNA precipitate and the tube was centrifuged 
at 13000 rpm for 5 minutes in room temperature in a Heraeus, Biofuge pico. 
 
6. The supernatant was removed and the DNA precipitate was air-dried for 30 minutes before 
it was delivered for sequencing. The Sequencing lab uses a 16 capillars machine, 3130xl 
Genetic Analyzer from Applied Biosystem HITACHI. 
  
3.2.14 DNA concentration measurements 
Ultrospec 2000 spectrophotometer from Pharmacia Biotech was used to measure the DNA 
concentration. The apparatus was calibrated and adjusted on the right wavelength according to 
the user manual. DNA is measured at a wavelength of 260 nm. A solution with an A260 of 1 
contains about 50 μg of DNA/ml [Sambrook and Russell 2001]. 
 
1. The DNA sample was diluted: 3 μl DNA + 57 μl sterile water 
 
2. A blank sample containing only 60 μl with sterile water was loaded into the cuvette. Then 





3. After the blank measurement, the DNA sample was pipetted into the cuvette.  
 
4. After the measurement the sample was sucked up again.  
 
5. Step 3 and 4 was repeated for each sample. 
 
6. After use the cuvette was cleaned with sterile water. 
 
 
Using the NanoDrop® ND-1000 Spectrophotometer was another apparatus used to measure 
the DNA concentration. One advantage with this method is that it is not necessary to dilute 
the sample before measuring. 
 
The “nucleic acid” was selected on the application module and the further measurements were 
performed according to the user manual.  
 
1. First, the instrument was made ready for use by loading a water sample onto the lower 
measurement pedestal.  
 
2. Before a sample measurement, a blank sample was loaded. A 1 μl blank sample with the 
same solvent used in the sample was loaded onto the lower measurement pedestal and the 
sampling arm was closed. Then the “Blank” button was clicked.  
 
3. The pedestals were wiped using a laboratory wipe. 
 
4. After making the initial blank measurement a 1 μl sample was pipetted onto the lower 
pedestal and the sampling arm was closed. Then the “Measure” button was clicked. 
 
5. When the measurement was completed the sampling arm was opened and the sample was 
wiped from the upper and lower pedestals using a laboratory wipe.  
 





3.2.15 Application of X-gal and IPTG onto agar plates. 
This is a method for identifying recombinant plasmids. Using X-gal that is converted by β-
galactosidase into an insoluble dense blue compound [Sambrook and Russell 2001] it will be 
possible to distinguish bacteria transformed by recombinant plasmids from empty plasmids 
(see introduction).  
 
1. 20 μl of 50mg/ml of X-gal and 50 μl of 100 mM IPTG was transferred to the centre of an 
agar plate containing appropriate antibiotic. 
 
2. A sterile spreader sealed in a flame was used to spread the solution over the entire surface 
of the plate.  
 
3. The plate was incubated for 30 minutes at 37 °C before the bacteria from the 
transformation procedure was applied (see 3.2.5). 
 
4. After an overnight incubation at 37 °C the plate was removed from the incubator and stored 
at 4 °C for several hours for the blue colour to develop. 
 
Blue colonies will contain plasmid vectors without insert, while white colonies contain 
plasmid vectors with insert. 
 
3.2.16 Making freezing stocks 
1 μl from the miniprep confirmed by sequencing containing the plasmid with the right insert 
and 
200 μl E. coli DH5α bacterial cells (see 3.2.5) were dispensed into a sterile falcon tube. 
 
100 μl was spread onto an agar plate containing the right antibiotic and incubated at 37°C 
overnight. 
One colony was picked and transferred into a tube of 3 ml LB medium containing the 






1.2 ml overnight culture was transferred into a cryon tube before 0.3 ml 50 % glycerol was 
added.  
 
The tube was stored at the –80 °C freezer 
 
3.2.17 BA/F3 mouse cells 
The BA/F3 cell line is a mouse pro B cell type. They have their origin from IL-3 dependent 
murine pro B cell line established from peripheral blood; apparently derived from BALB/c 
mouse. Their appearance is mostly single, round cells in suspension. The saturated culture is 
split 1:10 in fresh medium (see materials) every 3 days, and incubated at 37 ˚C in a 
humidified atmosphere with 5 % CO2. 
 
3.2.18 Electroporation of mammalian cells 
Electroporation is a mechanical method used to introduce DNA into a cell through the cell 
membrane. Techniques in molecular biology require a foreign gene or protein material to be 
inserted into a host cell. The phospholipid bilayer of the plasma membrane is amphipathic, 
meaning it has both a hydrophilic region and a hydrophobic region. The hydrophobic core of 
the membrane will make polar molecules, including DNA, unable to freely pass through the 
membrane [Campbell et al. 1999].  
 
To deal with this problem scientists have developed this method for introducing DNA into 
cells. In electroporation, a brief electrical pulse is applied to a solution containing the host 
cells and the molecules to be inserted into these cells. This electrical pulse disturbs the 
phospholipid bilayer of the membrane and creates temporarily aqueous pores in the cell’s 
plasma membranes, through which DNA or other molecules can enter [Campbell et al. 1999]. 
 
As molecules flow through the pores, the cell membrane discharges and the pores quickly 
close, and the phospholipid bilayer reassembles. Once inside the cell, DNA has a chance to be 







1. Two days prior to electroporation the cells were diluted into fresh growth medium (see 
3.2.17). 
 
2. At the day of electroporation the cell cultures were transferred to a centrifuge tube and 
pelleted by centrifugation at 1000 rpm for 4 minutes in a Heraeus, Labofuge 400 
(FUNCTION Line).  
 
3. The supernatant was removed and the cell pellet was washed in electroporation buffer 
(Opti-MEM) and centrifuged one more time at 1000 rpm for 4 minutes.    
 
4. The buffer was removed and the cell suspension was diluted in Opti-MEM to the calculated 
density of cells/ml.  
 
5. The calculated amount of plasmid DNA was added to the electroporation cuvettes (0,2 cm 
gap), thereafter the cell suspension was added 
 
6. The desired pulse condition on the Gene Pulser Xcell™ was set.  
 
7. The cuvette was tapped on the side to mix before it was placed in the electroporation 
device. 
 
8. A pulse of electricity was delivered to the cells once. 
 
9. Immediately after the pulse the cuvettes were rinsed with growth media and the cells were 
transferred onto the cell culture dishes.  
 
10. The dishes were incubated at 37°C in a humidified atmosphere, and checked for 








As described in the “aim of the study” the main purpose of this thesis was to develop an 
experimental system where the molecular and biological effects of the Glivec-resistant 
mutations in the Bcr-Abl could be studied. To do this we intended to use the MACSelect 
transfected cell selection and the mouse pro–B cell-line BA/F3 was used. 
 
To be sure that the system would work as intended, a pilot study with GFP cloned into the 
pMACS 4-IRES.II vector (see Figure 8) was performed.  
 
In the light of this the thesis is divided into two sections: 
• Cloning of GFP into the pMACS 4-IRES.II vector and electroporation of BA/F3 cells. 




4.1 Cloning of GFP into the pMACS 4-IRES.II vector 
 
The pMACS 4-IRES.II is an expression vector that contains an internal ribosome entry site 
(IRES) and a ΔCD4 encoding gene in addition to a multiple cloning site where the gene of 
interest can be cloned. The ΔCD4 gene encodes a transmembrane receptor with a truncated 
cytoplasmic domain. It has no possibilities to participate in signal transduction, but cells 
transfected with the cloned vector will co-express the CD4 markers on the cell-surface. By the 
use of magnetic beads with antibodies recognising the CD4 receptors one can select the 
transfected cells that co-express ΔCD4 along with the cloned gene of interest. When Green 
fluorescence protein (GFP) is cloned into the pMACS 4-IRES.II vector (see Figure 10), CD4 
positive cells will make fluorescent light that can be observed in a microscope with UV filter. 
The purpose of cloning GFP into this vector is to be able to easily monitor the transfection 
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Bacteria stocks containing either the pEGFP-C1 plasmid or the pMACS 4-IRES.II plasmid 
was grown in LB medium with appropriate antibiotics, and DNA minipreps were prepared as 
described in method 3.2.7. 
To cut out the GFP from the pEGFP-C1 vector (see Figure 7) the vector was first cut with 
NheI (see 3.2.1). Thereafter the fragment was made blunt-ended by filling the 5’ overhang 
with nucleotides, using T4 DNA polymerase (see 3.2.1). This would make it possible for the 
5’ end to ligate with the blunt end of the pMACS 4-IRES.II cut with EcoRV. Further the 
DNA fragment was cut with EcoRI. This separated the 760 bp NheI /EcoRI fragment from the 
pEGFP-C1 vector backbone. The pMACS 4-IRES.II vector was cut with EcoRI and EcoRV 
for 1,5 hours at 37°C before the vector was SAP treated to prevent religation of the vector in 
the ligation reaction (see 3.2.1). The DNA was separated on a 0,7 % agarose gel (see 3.2.2) 
for about 30 minutes (see Figure 11). Two bands were observed for pEGFP-C1. The upper 
band indicated rest of the pEGFP-C1 vector, while the lower band indicated the fragment 
containing the fragment of interest, the GFP gene. This 760 bp GFP-fragment with a blunt end 
and a staggered EcoRI 3’ end, and the linearized pMACS 4-IRES.II vector on 5841 bp was 
cut out and purified using QIAquick Gel Extraction Kit (see 3.2.3).  
 
 
Figure 11. The GFP cut out from the pEGFP-C1 vector. The GFP in lane 2 is cut out from the 
pEGFP-C1 vector with NheI and EcoRI. Two bands are formed, the upper band indicate rest of the 
pEGFP-C1 vector on about 4000 bp, while the lower band on 760 bp indicate the GFP insert. The 
band formed in lane 1, on almost 6000 bp, indicates the pMACS 4-IRES.II vector cut with EcoRI and 




The purified GFP-NheI/EcoRI fragment was then ligated into the pMACS 4-IRES.II- EcoRI / 
EcoRV vector (see 3.2.4). The ligation reaction was transformed into competent E. coli DH5α 
cells as described in method 3.2.5, and plated onto media with ampicillin.  
 
Single colonies were picked from the plates and were grown over night. Plasmid DNA was 
purified using Miniprep Kit (see 3.2.7). To test for plasmid DNA with correct insert, purified 
DNA was digested with NdeI and EcoRI. The NdeI recognition site is located 500 bp from the 
insert (see Figure 12 ). The resulting DNA fragments were separated on a 0,7 % agarose gel 
(see 3.2.2) to confirm whether the cloning of GFP into pMACS 4-IRES.II vector had been 
successful. It was expected to see two bands, one band on about 1300 bp and one band on 
about 6000 bp. The results show that four of the seven minipreps (lanes 3, 4, 5 and 7) have 
bands on the right size, 1268 bp and 5841 bp (see Figure 12). The minipreps with other band 


















Figure 12. Cloning of GFP into pMACS 4-IRES.II. A. A sketch showing the GFP gene cloned into 
the pMACS 4-IRES.II vector with the NdeI restriction site located 500 bp from the insert. The plasmid 
is drawn as a line, while the incorporated GFP gene is drawn as a rectangle. Restriction enzyme put in 
parenthesis indicates that the end is made blunt. B. The GFP insert is cut out from the pMACS 4-
IRES.II vector with NdeI and EcoRI. The NdeI sequence site is located 500 bp from the insert and will 
form the GFP band on about 1300 bp, while the pMACS vector is expected to form a band on about 
6000 bp. The results show that the samples in lane 3, 4, 5 and 7 have an insert on the expected size.  
 
Minipreps 3 and 4 were sent for sequencing (see 3.2.13) and confirmed positive before 
freezing stocks were made and stored at the –80 °C freezer (see 3.2.16).  
 
Based on the overnight cultures used to make miniprep 3 with correct insert, preparation of 







4.1.1 Optimization of electroporation of BA/F3 mouse cells 
We wanted to test the electroporation protocol for electroporation of BA/F3 cells with 
pMACS-GFP and pEGFP-C1. 
 
For a long time it was a problem that the transfection method did not work as intended. 
pEGFP-C1 was successfully transfected into the cells producing fluorescent cells, while the 
pMACS-GFP formed no green cells when used for electroporation. To verify that GFP was 
produced from the pMACS-GFP plasmid HeLa cells were transfected with pMACS-GFP. The 
transfection efficiency was poor, but green fluorescent cells were observed (result not shown) 
indicating that the pMACS-GFP plasmid is functional.  
 
After additional optimization of the electroporation method it was still difficult to see green 
cells when pMACS-GFP was transfected, but the electroporation of pEGFP-C1 must be 
considered as successful (see Figure 13).  
 
 
Figure 13.  Pictures showing the transfection of pEGFP and pMACS-GFP into BA/F3 mouse 
cells.  A. Fluorescent picture showing the BA/F3 cells successfully transfected with the pEGFP vector. 
B. Brightfield picture showing all the cells independent of whether they are transfected or not. 5 μg 
plasmid, 1 x 10-7 cells in 200 μl cell suspension. C.  Fluorescent picture showing the BA/F3 cells 
successfully transfected with the pMACS-GFP vector. D.  Brightfield pictures showing all the cells 
independent of whether they are transfected or not. 10 μg plasmid, 1 x 10-7 cells in 200 μl cell 




4.2 Cloning of Bcr-Abl into pBluescript(KpnI-).  
 
The primary goal of the project was to clone the 6000 bp Bcr-Abl into the pMACS 4-IRES.II 
vector. Once inside the vector, the construct was going to be transfected into BA/F3 cells. 
Due to the vector system used, transfected cells that express the Bcr-Abl gene will be selected 
by the help of the magnetic beads since they co-express the CD4 molecule at the cell surface. 
This selection will make sure that all the further downstream experiments are done with cells 
expressing Bcr-Abl, since non-transfected cells are not selected.  
 
Cloning such a large fragment is intricate; in addition, the vector is large and difficult to clone 
into. So the cloning strategy for the Bcr-Abl gene is first to clone it into pBluescript(KpnI-), 
and thereafter transfer it into the pMACS 4-IRES.II vector (see Figure 14).  
 
The pBluescript II KS vector (see Figure 6) contains one KpnI sequence in the multiple 
cloning site. By cutting pBluescript with KpnI and making this site blunt before self-ligation, 
the KpnI sequence in the MCS region was destroyed. This was done so that the only KpnI site 
in the Bcr-Abl fragment later can be used, together with AatII, for subcloning of the P-loop 
mutants. All the mutants we are interested in studying are situated between the KpnI and 
AatII restriction sites in the Bcr-Abl gene. When the KpnI sequence in the MCS region of the 
pBluescript is destroyed, it is possible to subclone mutants from patient material into 
pBluescript(KpnI-)/Bcr-Abl by cutting the mutants with KpnI and AatII. The 
pBluescript(KpnI-) /Bcr-Abl is opened by cutting with the same restriction enzymes.  
 
Provided that the subcloning into pBluescript(KpnI-) is successful the mutants can be further 
cloned into the pMACS 4-IRES.II vector by cutting both pMACS 4-IRES.II and 
pBluescript(KpnI-)/Bcr-Abl with EcoRI and EcoRV. 
 
Because the Bcr-Abl gene is so large the cloning has to be done in a stepwise order. 
According to where the restriction sequences were situated, the Bcr-Abl gene was divided 
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Figure 15. A general drawing of the Bcr-Abl gene showing the different primer combinations, the 
KpnI restriction site, the division of the three fragments, and the p-loop where the mutants we are 




4.2.1 Construction of pBluescript(KpnI-) 
The pBluescript vector was cut with KpnI, and then made blunt using T4 DNA polymerase 
(see 3.2.1). This would make it possible for the vector to religate and destroy the original 
KpnI site thereby creating pBluescript(KpnI-). The vector was run on a 0,7 % agarose gel 
(results not shown). The band of 3000 bp was cut out from the gel and purified using 
QIAquick Gel Extraction Kit (see 3.2.3). Thereafter the pBluescript vector was self-ligated to 
generate pBluescript(KpnI-) (see 3.2.4). The ligation reaction was transformed into competent 
E. coli DH5α cells (see 3.2.5). DNA from ampicillin resistant colonies was purified using 
standard DNA miniprep before the plasmid was test cut with KpnI. If the cloning has been 
successful, KpnI will no longer be able to cut the pBluescript vector. The digested DNA preps 
were separated on a 0,7 % agarose gel. The results shown in Figure 16 show that two of the 
four minipreps (lane 4 and 5) have the same band size as the control (lane 6), which is uncut 
pBluescript. The samples in lane 2 and lane 3 have the same band size as the pBluescript cut 






Figure 16. Restriction analysis to confirm the construction of the pBluescript(KpnI-). The 
pBluescript vector was first cut with KpnI to destroy the KpnI sequence in the MCS region in the 
vector before it was relegated to construct pBluescript(KpnI-). The pBluescript vector is 3000 bp in 
size. The results were run on a 0,7 % agarose gel and show that two of the samples have the same 
band size as the pBluescript cut with KpnI, and the other two samples have the same band size as the 
uncut pBluescript vector. The samples in lanes 2 and 3 have bands of about 3000 bp, the same size as 
the pBluescript vector in lane 1 that is cut with KpnI. The samples in lane 4 and lane 5 show two 
bands with a band size similar to the uncut pBluescript in lane 6. The samples in lane 4 and 5 show the 
correct bands, KpnI shall no longer be able to cut the pBluescript vector in the KpnI site. This means 
that the construction of pBluescript have been successful in two of the four minipreps.  
 
To be sure that the samples in lanes 3 and 4 were pBluescript vector with destroyed KpnI sites 
minipreps of 3 and 4 were sent for sequencing (see 3.2.13). When also sequencing confirmed 
the pBluescript vector had a non-functional KpnI site, freezing stocks were made and stored 
in the –80 °C freezer (see 3.2.16). 
 
4.2.2 PCR on Bcr-Abl to generate the A, B and C fragments for cloning. 
Primers containing appropriate restriction enzyme sites were generated and used for PCR to 
amplify the A, B and C fragments of Bcr-Abl. Different primer combinations were used to; if 
possible, generate larger parts of Bcr-Abl in one single PCR reaction. pEYKBA was used as 
template. To see which of the fragments that had been successfully amplified the PCR 
products were separated on a 0,7 % agarose gel for 1 hour. The results showed in Figure 17 
show that the B-fragment, the C-fragment and the BC-fragment had been successfully 
amplified using this method. However, there were no signs neither of the A-fragment nor the 
whole Bcr-Abl gene. The Bcr-F(EcoRV) primer has misannealed, probably because of 






Figure 17. Amplification of the different fragments in the Bcr-Abl gene using different primers. 
The PCR products from the amplification of the different fragments of Bcr-Abl show that only the B 
fragment in lane 3, the C fragment in lane 4 and the larger fragment in lane 5 containing both the B 
and C fragment have been successfully amplified. The A fragment consists of 1700 bp, but there is no 
sign of the fragment in lane 2. The whole Bcr-Abl gene in lane 6 is not visualized either.  
 
The BC-fragment was cloned directly into the pCR® XL-TOPO® vector, which is 
recommended for cloning of large PCR products.  
 
Before the BC-fragment could be cloned into the pCR® XL-TOPO® vector (see Figure 9) it 
had to be gel purified. Here two alternative strategies were considered. To avoid damaging the 
DNA by UV light the PCR products were run on a 0,8 % agarose gel using crystal violet from 
the TOPO® XL PCR Cloning Kit (see 3.2.11). This gel was run parallel to a traditional 0,7 % 
ethidium bromide agarose gel. Using crystal violet the PCR product are visualized on the 
agarose gel under normal light and can be excised as soon as they are sufficiently resolved. 
Agarose gel electrophoresis using crystal violet turned out to be easier said than done. No thin 
blue bands were visualized on the gel so the BC fragment was not possible to excise out from 
the gel. The result of this was that fresh PCR product, instead of purified PCR product, first 
was cloned into pCR® XL-TOPO® vector and further chemically transformed into One 





For analysing the clones, colonies were picked and cultured overnight in LB medium. 
Thereafter the plasmids were purified using Miniprep Kit (see 3.2.7). Finally, the plasmids 
were cut with KpnI and separated on a 0,7 % agarose gel (see Figure 18) (see 3.2.2). The 
restriction enzyme KpnI cut once in the vector and once in the inserted BC-fragment. 
Depending on which way the BC fragment is inserted into the TOPO®-XL vector the KpnI 
digest will give bands of different sizes. The result gave either one band of about 1500 bp in 
combination with one band of about 6500 bp, or bigger bands of 3000 and 5000 bp were 
produced, depending on which way the insert was oriented (see Figure 18). All the minipreps 
contained inserts, but as seen from the restriction pattern the inserts were oriented different 
ways in the vector. The orientation of the insert does not matter for the further procedure, so 
we chose to sequence miniprep 2. As soon as the sequence was verified a freezing stock was 
















Figure 18. Restriction analysis to confirm the insert of the BC-fragment in pCR® XL-TOPO® 
vector. A. There is a KpnI site localized 50 bp away from the cloning site in the vector. And in the BC 
fragment there is a KpnI site in nucleotide position 1500. Depending on which way the BC fragment is 
inserted, the KpnI enzyme will therefore produce fragments of 1500 + 6500 bp, or at 3000 + 5000 bp. 
The TOPO vector (3500 bp) is drawn as a line, while the BC fragment is drawn like a rectangle. B. 
The DNA minipreps screened for BC-fragment insert in the pCR® XL-TOPO® vector was digested 
with KpnI and run on a 0,7 % agarose gel. All the minipreps contain inserts, but the restriction pattern 
is different. This is because the inserts are oriented in two different ways in the vector. Minipreps 2, 4, 
6, 8 and 11 all contain inserts with the same direction, while minipreps 3, 5, 7, 9 and 10 have the 
fragment inserted in the opposite direction.  
 
4.2.3 Revised strategy for cloning the A-fragment 
Since two-thirds of the Bcr-Abl fragment now was successfully cloned, we focused on the 
remaining part of the gene, the A fragment.  
When the first attempt to amplify the A fragment failed, a new PCR was set up, using another 
forward primer (see 3.2.10). When this amplification also failed a new strategy was made. 
The Bcr-Abl containing plasmid pEYKBA was cut with FseI since the Bcr-Abl genome 




(see Figure 19). Thereafter the fragment was made blunt-ended using T4 DNA polymerase, 
before it was cut with SacI (see 3.2.1). This should give us a 1700 bp FseI(blunt)-SacI 
fragment (the A-fragment), which can be ligated to the pBluescript plasmid cut with EcoRI, 
blunted and thereafter cut with SacI. The fragments were separated on a 0,7 % agarose gel 
(see Figure 19) . For Bcr-Abl two bands were observed, and the lowest band was cut out from 




Figure 19. The A fragment cut out from a Bcr-Abl containing plasmid. Lane 2 shows the A 
fragment of about 1700 bp cut out from the Bcr-Abl plasmid. The Bcr-Abl plasmid was first cut with 
FseI, thereafter the fragment was made blunt before it was cut with SacI. The pBluescript vector in 
lane 1 was first cut with EcoRI, made blunt and then cut with SacI. The pBluescript indicating the 




For pBluescript the 3000 bp linearized plasmid was cut out and purified, before the A-
fragment was ligated into the pBluescript vector. The ligation reaction was transformed into 
competent E. coli DH5α cells as described in method 3.2.5, and amp-resistant colonies were 




SacI and EcoRV was used for test cutting. The results were separated on a 0,7 % agarose gel. 
SacI and EcoRV will cut out the A fragment from the pBluescript vector. As can be seen from 
Figure 20B, the samples in lane 7 and lane 11 have an insert of the expected size. Miniprep 7 
was sent for sequencing, and was confirmed to contain the 5’ part of Bcr corresponding to the 
A fragment. However it turned out that in front of the A fragment, 256 bp of the original Bcr-
Abl vector was included. This is because the FseI site did not exist just in front of Bcr-Abl, 
but about 250 bp further upstream. This may explain why the molecule weights of the A 
fragment in figure 19 (lane 2) and figure 20 (lane 7 and 11) is a bit higher than expected. 
















Figure 20. The A fragment cut out from the pBluescript vector.  A. A sketch showing the A 
fragment cloned into the pBluescript vector. The vector is drawn as a line, while the A fragment is 
drawn as a rectangle. The restriction enzymes put in parentheses indicate ends made blunt. B. Cutting 
out the A fragment from the pBluescript vector with SacI and EcoRV. Lane 7 and lane 11 show 
vectors with insert at the correct band size. The bands shown are about 2000 bp and 3000 bp, 





4.2.4 Cloning the A fragment and the BC fragment into the pBluescript(KpnI-) vector 
Now the A fragment is cloned into the pBluescript vector and the BC fragment is cloned into 
the pCR® XL-TOPO® vector. The next step will be to cut these two fragments out from their 
vectors and clone them into the constructed pBluescript(KpnI-) vector so that a continuous 
Bcr-Abl gene segment is made (as illustrated in Figure 21). The fragments are cloned into their 
vectors in a way that will make it possible to ligate the two fragments together into the new 
vector by cutting each fragment with their specific restriction enzymes.          
 










Figure 21. A sketch showing the different restriction sites and how the A fragment and the BC 




First, the BC fragment was cut out with SacI and EcoRI, the A-fragment was cut with SacI 
and EcoRV and the pBluescript(KpnI-) was cut with EcoRI and EcoRV. When separated on a 
0,7 % agarose gel (see Figure 22) different band sizes were seen. The A fragment in lane 1 
formed two bands where the upper band contained the pBluescript vector (3000 bp) and the 
lower band indicated the A-fragment. Two bands were also formed in lane 2 and lane 3 with 
the BC fragment. The lower band contained the pCR® XL-TOPO® vector (3500bp) and the 
upper band indicated the BC-fragment. In lane 4 with the pBluescript three different 
conformations of the vector were observed, probably due to incomplete digestion of the 
plasmid DNA. The A fragment, the BC fragment and the pBluescript(KpnI-) vector of about 






Figure 22. A gel verifying the correct band sizes of the A fragment, the BC fragment and the 
pBluescript(KpnI-) vector. Lane 1 shows the A fragment cut out from pBluescript with EcoRV and 
SacI. Two bands are observed, one band at 3000 bp and the other band at about 1700 bp. The upper 
band indicates the pBluescript vector, while the lower band indicates the A-fragment. The A-fragment 
was cut out from the gel. Lane 2 and lane 3 indicate the BC-fragment cut out from the XL-TOPO 
vector with SacI and EcoRI. The upper band on about 4500 bp indicates the BC-fragment, and the 
lower band on 3500 bp indicates the vector. The BC-fragment was cut out from the gel. When it 
comes to the three bands in lane 4 they indicate the pBluescript(KpnI-) vector in three different 
conformations. The pBluescript(KpnI-) band in the middle, on approximately the same level as the 
pBluescript vector in lane 1, was cut out and purified together with the other band cut out. The upper 
band > 3000 bp is probably not completely cut plasmid, and the lowest < 3000 bp, supercoiled uncut 
plasmid.  
 
When it came to the ligation of the A-fragment and the BC-fragment into the 
pBluescript(KpnI-) it proved to be unexpectedly difficult.  
 
First a ligation mix containing only the two fragments, A and BC, the DNA ligase and the 
ligase buffer was left for 1 hour in room temperature before the pBluescript(KpnI-) vector was 
added. This was done in order to increase the chances for ligation between the two fragments. 
The ligation reaction was left over night at 14 ˚C and transformed into competent E. coli 
DH5α cells and plated onto media with ampicillin. Single colonies were grown and purified 
using Miniprep Kit (see 3.2.7). To test for plasmid DNA with correct inserts, purified DNA 




one band on 3000 bp (results not shown). It was expected to see two bands, the vector on 
3000 bp and the insert on approximately 6000 bp. The vectors are probably relegated. 
 
The pBluescript(KpnI-) was once again cut with EcoRI and EcoRV treated with SAP (see 
3.2.1) and purified from agarose gel before ligation in case the observed relegation arose from 
improper dephosphorylation of the vector.  
 
A new ligation mix with the A fragment and the BC fragment was one more time tried to be 
ligated with the new pBluescript(KpnI-) vector. The transformation into E. coli cells gave 
good growth and 10 colonies were picked from the plates and grown over night. Plasmid 
DNA was purified (see 3.2.6) and to test for correct insert the plasmid DNA was digested 
with EcoRI and EcoRV. The results were analyzed on a 0,7 % agarose gel. Again two bands, 
of 3000 bp and 6000 bp were expected. The result (not shown) showed only one band on 
3000 bp, the same size as the control that indicated the pBluescript(KpnI-). Probably only one 
of the restriction enzymes had worked and made a linearized plasmid with two 
complementary ends.  
 
The recognition sites for EcoRI and EcoRV in the pBluescript(KpnI-) vector are very close.  
Maybe the binding of one enzyme will prevent the binding of the other so that only one of the 
two restriction enzymes has worked. In that case the vector is only linearized and will have 
two ends that can base pair with each other. It will be impossible to clone the Bcr-Abl gene 
cut with EcoRI and EcoRV into the pBluescript(KpnI-) and the likelihood for that the vector 
will relegate is big. It is not possible to see if both the restriction enzymes have cut on their 
sequence sites just by looking at the gel. 
 
After a number of unsuccessful attempts to clone the two fragments together in 
pBluescript(KpnI-) different  strategies were tried out. 
 
Since it might be a problem ligating big fragments in one ligation reaction, we wanted to try 
to clone the A fragment into the pCR® XL-TOPO® vector with the BC fragment instead, and 
then transfer the ABC fragment to pBluescript(KpnI-) and pMACS  4-IRES.II as first planned.  
 
Since the A fragment had to be cut out from the pBluescript vector with SacI and ligated to 




TOPO® vector had to be destroyed.  To do this, the BC fragment had to be cut out from the 
pCR® XL-TOPO® vector with EcoRI, before separating the DNA fragments on a 0,7 % 
agarose gel. Two bands of 3500 and 4500 bp, indicating the pCR® XL-TOPO® vector and 
the BC fragment, were observed as expected (results not shown). When cut out from the gel 
and purified (see 3.2.3) the pCR® XL-TOPO® vector was self-ligated and transformed into 
competent E. coli DH5α cells and then plated onto media with kanamycin. The intention was 
to purify the XL-TOPO vector and destroy the SacI site before the BC fragment was relegated 
into the EcoRI site. Then the pCR®-XL-TOPO(SacI-)-BC vector could be opened with SacI 
and EcoRV, and the A fragment digested with the same enzymes could have been inserted. 
When the whole Bcr-Abl gene is cloned into the pCR® XL-TOPO® vector and transformed 
into competent E. coli DH5α cells the gene can be transferred to the pMACS 4-IRES.II vector 
using the restriction enzymes EcoRI and EcoRV. 
 
The problem with this strategy was to grow the colonies containing self-ligated EcoRI 
digested pCR-XL-TOPO onto medium with kanamycin. After several overnight incubations 
at 37 ˚C there were no colonies on the plates, indicating that the self-ligation of the vector had 
failed. The kanamycin containing plates were tested with other bacteria containing kan-
resistance, and found to be OK.   
 
Another unsuccessful attempt to clone Bcr-Abl gene into pBluescript was done. This time the 
A fragment and the BC fragment were ligated before the fragment was amplified using PCR 
(see 3.2.10). A PCR product would only be seen if the A fragment and the BC fragment had 
been properly ligated to each other. The PCR products were intended to be cloned into 
pBluescript following the usual procedure with transformation, purification of the plasmid 
DNA, digestion of the plasmid DNA and the vector with specific restriction enzymes, gel 
purification and ligation into the pBluescript(KpnI-). However the PCR product was run on a 
0,7 % agarose gel there was no sign of the sample, so the attempt was terminated.  
 
As a final experiment, several ligation reactions were set up in an attempt to increase the 
number of correct ligation products. The usual ligation procedure was followed and different 
amounts and concentrations of plasmid vectors and DNA inserts in a total volume of 50 μl 





Table 4. The different amounts and concentrations used in the ligation reactions 
 1 2 3 4 5 6 
A (9,3 ng/μl) 2 μl 3,5 μl 2 μl 3,5 μl 3,5 μl 3,5 μl 
BC (8,6 ng/μl)) 4 μl - 4 μl 8 μl - - 
BC (7,1 ng/μl)) - 8,5 μl - - 8,5 μl 8,5 μl 
pBluescript(KpnI-) 
(0,7 ng/μl)) 
14 μl 14 μl - - - - 
pBluescript(KpnI-) 
(13,5 ng/μl)) 
- - 1 μl - 2,5 μl - 
pBluescript(KpnI-) 
(28,3 ng/μl)) 
- - - 1,5 μl - 2 μl 
 
To increase the chances for ligation of the A and BC fragments with each other, the fragments 
were incubated with ligase for 1 hour before the vector was added.  
 
An overnight ligation was set up and the ligation mixes were transformed into competent 
DH5α E. coli cells. It was growth on all the plates, but the plates with the vectors with the 
highest concentration had most colonies. Three colonies were picked from each plate and 
purified. The purified DNA plasmids were run on a 0,7 % agarose gel to find out which of the 
plasmids that had an insert. A sample with pBluescript(KpnI-) was used as a control. All the 
minipreps originating from ligation mix 1 and 2 (see Table 4 ) migrated more slowly in the 
gel than the vector control did, indicating that they contained an insert. The other twelve 
minipreps formed band at the same size as the pBluescript(KpnI-), showing that the vector 
probably had religated containing no insert (see Figure 23A). The six minipreps from ligation 
mix 1 and 2 were test cut with (a) EcoRI and EcoRV to cut out the insert and (b) only with the 
EcoRI to linearize the vector with the insert. After digestion, the minipreps were run on a 0,7 
% agarose gel. As can be seen from Figure 23B the bands formed in lane 2 to lane 7 are about 
5000 bp indicating that the vectors are linearized and contain an insert on about 2000 bp. The 
Bcr-Abl gene is 6000 bp so it cannot be the whole gene, but it might be the A fragment. In 
lane 8 to lane 13 two bands are formed. The upper band indicated nicked plasmid, while the 
lower band indicated supercoiled plasmid. The EcoRI has not worked so the vector is still 
circular. One of the minipreps in lane 2-7 was sent for sequencing and it was confirmed that it 
was only the A fragment that was cloned into the pBluescript(KpnI-) vector, and that the 




fragment was cut out from the pBluescript with EcoRV and SacI. Theoretically these two 
fragments are not supposed to ligate and form a circular plasmid. In a way the SacI end of the 
fragment must have been made blunt, and so must the other ends as well. To select for clones 
that had insert in their vectors a so-called blue-white screening was done (see 3.2.15). After 
an overnight incubation there were a lot of colonies on the plate, but none of them had turned 
blue. It was unlikely that all the clones had insert in their vectors. Because of the time limit in 










Figure 23. The pBluescript(KpnI-) vector controlled for correct insert. A. The minipreps in lane 2-
7 (from ligation mix 1 and 2) are different from the control with pBluescript(KpnI-) in lane 1 and the 
other minipreps in lane 8-19. The bands formed in lane 2-7 are about 2000 bp larger than the other 
minipreps, indicating that they contain an insert. B. Lane 1 shows the pBluescript(KpnI-) control on 
3000 bp. The sample in lanes 2-7 show the minipreps from ligation mix 1 and 2 (Table 4) cut with 
EcoRI and EcoRV. Bands on about 5000 bp indicate that the vectors are linearized and contain an 
insert on about 2000 bp. Lane 8 to lane 13 contain minipreps from ligation mix 1 and 2 (Table 4) cut 
with only EcoRI. Two bands are observed (> 3000 bp and <3000 bp) a typical pattern for undigested 







As a short summing up, in the pilot study the GFP was successfully cloned into the pMACS 
4-IRES.II vector, but the further transfection of pMACS-GFP into the BA/F3 cells was not 
satisfactory. The only successfully transfection into the BA/F3 cells was the pEGFP-C1 
vector used as a control. 
 
When it comes to the Bcr-Abl gene the challenge was to clone this 6000 bp long fragment 
into the pMACS 4-IRES.II vector. The A fragment and the BC fragment were separately 
cloned into two different vectors, but the placing of the restriction sites made it difficult to 
ligate these two fragments into the same vector. The A fragment was cloned into the 
pBluescript(KpnI-) vector, but the EcoRI site was destroyed and made it difficult to clone the 








The constitutive tyrosine kinase activity of the Bcr-Abl fusion protein is the causative agent of 
CML. A small tyrosine kinase inhibitor, imatinib, Glivec, has shown to be remarkably 
effective in the treatment of the disease; it induces hematologic in over 90 % and cytogenetic 
remission in over 80% of all CML patients [Kantarjian et al. 2002], but clinical resistance to 
imatinib treatment has become a significant problem [Shah et al. 2002]. The main reason for 
resistance is single point mutations in the Abl gene encoding the ATP binding region, which 
is also the binding site for imatinib. How and why these point mutations arise is not known, 
but increasing evidence suggests that cells with pre-existing mutations are selected rapidly 
during imatinib treatment [Shah et al. 2002; Roche-Lestienne et al. 2004]. In addition, a 
distinct group of patients with P-loop mutations have a poorer prognosis [Branford et al. 
2003; Soverini et al. 2005]. Early detection of these mutations and re-evaluation of treatment 
options are of particular interest for this group of patients. It is still not known if P-loop 
mutations represent increased fitness mutations rendering Bcr-Abl more aggressive or if the 
reduced survival is a matter of inadequate treatment. The imatinib resistance due to mutations 
has led to the development of a second generation of targeted CML drugs [Shah et al. 2002]. 
In this respect, the emergence of mutated Bcr-Abl clones in the setting of imatinib resistance 
raised many questions.  
 
Our intention was to look more closely on how the different point mutations affect the gene 
expression. Thus, the aim of this project was to clone the Bcr-Abl and subsequently subclone 
some of the interesting point mutations found in Bcr-Abl and expresses them in BA/F3 cells. 
To identify genes regulated by Bcr-Abl we wanted to employ microarray analysis to compare 
the wild type and the mutated forms of Bcr-Abl in the mouse pro-B cell line and see if there 
were any differences in the gene expression profile. Kinase assay or the activation of the 
different signalling pathways could have been checked by the use of Western blot analysis of 
phosphotyrosine levels in transfected BA/F3 cells.  
 
The Bcr-Abl tyrosine kinase affects the same pathways in the cells as the abl tyrosine kinase. 






5.1.1 Electroporation of pMACS-GFP into BA/F3 cells 
The electroporation of pMACS-GFP into the BA/F3 cells did not work out as expected, but 
the transfection of pEGFP-C1 into the same cells worked well. The reason for this is difficult 
to say for sure, but there are a number of factors that can be decisive for the results. 
 
Electroporation is a process in which a high voltage current is used to open pores in the cell 
membrane in order to introduce nucleic acids, proteins and other membrane-impermeable 
molecules. The strength of the applied electric pulses can both be too high and too low. The 
electric pulses must be strong enough to cause permeabilization but not so intense that the 
membrane fails to reseal and the cell dies [Sambrook and Russell 2001].  
Transfection efficiency and cell viability is influenced by a number of factors. In addition to 
the intensity of the electric pulses, the frequency and pattern of the electric pulses must be 
optimized to allow enough time for the plasmid to enter, and at the same time be short enough 
to prevent the cell from losing its contents, which can cause irreversible damage to the 
membrane. Temperature, the concentration of DNA and other factors can also influence the 
results during electroporation varying with the type and size of cells used [Sambrook and 
Russell 2001]. Another factor is that methods from protocols designed to a particular 
instrument can be difficult to adapt to other instruments. 
 
The pMACS 4-IRES.II vector is a big (5841 bp) vector, and when the GFP is incorporated it 
is over 6000 bp. When the Bcr-Abl gene is inserted the vector will be even bigger. We do not 
know if it is the size that is the problem, but if so it can be even more difficult to transfect the 
BA/F3 cells with the pMACS vector when the Bcr-Abl gene is incorporated. Since the 
pEGFP-C1 vector (4731 bp), which also is a relatively big vector, has been successfully 
transfected into the BA/F3 cells, it might be another reason for the unsuccessful attempt in 
transfecting the pMACS-GFP into the BA/F3 cells, but as discussed above there are several 
factors that can influence the transfection efficiency. 
 
When we managed to transfect the HeLa cells with the pMACS-GFP we proved that the 
system with GFP worked. The HeLa cells transfected with the pMACS-GFP made fluorescent 





Why it is easier to transfect the HeLa cells compared to the BA/F3 cell is difficult to say, but 
different cell types takes up foreign DNA to various degrees. While the HeLa cells originate 
from cancer cells in the uterus, we used BA/F3 pro-B cells similar to the cells where the Bcr-
Abl naturally occurs. Another decisive factor for using the BA/F3 cells is that they grow in 
suspension in difference to the HeLA cells that are adherent. To detach them from the plastic 
surface trypsin, a protease, which can degrade the CD4 receptors from the cell surface, is 
used. In suspension the BA/F3 cells are free to co-express the CD4 receptors and are therefore 
more suitable for our work. 
 
5.1.2 Amplifying the Bcr-Abl gene using PCR 
Given the large size of the transcript, the cloning of Bcr-Abl was not expected to be 
straightforward. Well aware of all the problems cloning of long products could offer, we 
carefully tried to design a stepwise cloning procedure. The first part consisted of a PCR 
amplification step, which according to our plans should be carried out in amplification of 
three fragments, each stretching a little more than 2000 bp. The primers used for amplification 
of these fragments were located in relation to the start- and stop codons respectively. Each of 
these primers contained recognition sites for restriction enzymes, which at a later stage would 
allow cloning the fragments. Furthermore, we identified unique restriction sites within the Bcr 
and Abl transcript. Additional pairs of forward and reverse primers were designed stretching 
these sites. According to this strategy PCR products could be digested with the respective 
enzymes after the amplification step and cloned into a vector, which was opened using the 
same enzymes. Unfortunately, using this strategy, primers had to be designed for annealing to 
well-defined sequences, rather than designing primers, which were optimized for maximal 
efficiency.  
 
This method worked well for amplifying the BC fragment, but in case of the A fragment the 
PCR primer turned out to be unspecific. Misannealing of the Bcr-F(EcoRV) primer, at the 
start of the Bcr gene, resulted in a false small PCR product that did not contain the sequences 
in the beginning of the Bcr gene. Annealing of long strands can lead to unspecific products 





5.1.3 Cloning of long PCR products 
The cloning of PCR amplified fragments into a plasmid vector is a routine procedure in 
recombinant DNA cloning, but all PCR fragments will not clone with the same efficiency, 
and there are various reasons for this. After searching the Internet for advice and hints about 
cloning long PCR fragments it is evident that problems with cloning long PCR product is a 
quite common problem. As already mentioned, the size of the fragment to be cloned is of 
importance, but also the complexity of the cloning strategy needs to be considered.  
 
 “TOPO® Cloning”, used when cloning the BC fragment, is an efficient method for cloning 
PCR products into a plasmid vector and is specifically designed to clone long PCR products. 
Taq DNA polymerase adds a single deoxyadenosine to the 3’ ends of the PCR product and 
produce specific DNA sequences with 3’ A overhangs. Using TOPO Cloning the PCR 
products are ligated into a linearized plasmid vector with 3’ deoxythymidine overhangs 
activated by topoisomerase I. This method worked well for the BC fragment, and if the whole 
Bcr-Abl had been amplified in one single PCR reaction, we would have cloned the whole 
gene into a pCR® XL-TOPO® vector 
 
But the misannealing of the A fragment prevented us from isolating and amplifying the full-
length Bcr-Abl gene using PCR, and forced us to try another strategy for the cloning of the A 
fragment. When the use of PCR failed in amplifying the A fragment it had to be cut out from 
the Bcr-Abl plasmid instead. This resulted in two long fragments to clone into the 
pBluescript(KpnI-) vector which is much more complicated than cloning just one fragment. 
 
It would probably have been much easier to clone the Bcr-Abl into the pBluescript(KpnI-) if it 
first was cloned into the XL-TOPO vector in one fragment. This is why we tried to ligate the 
A fragment into the XL-TOPO vector with the BC fragment. However, this proved to be 
much more difficult than expected. 
  
Not only was the Bcr-Abl gene to be cloned long, but also the pMACS 4-IRES.II vector is big 
(see Figure 9). Cloning Bcr-Abl into this vector could also have offered some problems. 
There were two reasons for using the pBluescript(KpnI-) vector. The pBluescript vector is 




pBluescript(KpnI-)-Bcr-Abl could be used to subclone the mutants by switching the KpnI-
AatII fragment between the pBluescript(KpnI-) and the pMACS 4-IRES.II vector.  
 
5.1.4 The position of the restriction sites 
When cloning this 6000 bp long fragment into one vector there are, as already mentioned, 
different challenges to handle. Cloning more than one fragment into one vector is a factor that 
complicates the strategy. In a ligation reaction where different fragments are supposed to 
ligate and form a circular DNA molecule the strands cut with the same enzyme will have 
complentary ends that can base pair and form phosphodiester bonds. The longer the fragments 
are even more difficult will it be to get the right ends to ligate and orientate.  
 
In our case the recognition sites for EcoRI and EcoRV in the pBluescript(KpnI-) vector were 
positioned very close to each other. This was probably an affecting factor for the difficulties 
in cloning the Bcr-Abl into the vector. If the binding of one enzyme prevent the binding of the 
other enzyme the pBluescript(KpnI-) vector will be opened, but only with one of the 
restriction enzymes. This will form a linearized vector with two ends that can easily base pair 
with each other and make a relegated vector containing no insert. Cloning the Bcr-Abl gene 
cut with EcoRI and EcoRV into this pBluescript vector is theoretically impossible when there 
is only one matching end. A linearized fragment where the matching end of the insert is 
ligated with one of the vector ends can form, but the vector cannot ligate and form a circular 
plasmid 
 
5.1.5 Future direction 
As mentioned earlier in this discussion, the preferred strategy would be to amplify the whole 
Bcr-Abl gene in one single PCR reaction and then clone it directly into the XL-TOPO vector, 
designed for cloning of long PCR products. Thereafter the Bcr-Abl fragment could have been 
subcloned into pBluesscript(KpnI-) and pMACS 4-IRES.II. In the future, a possible way to do 
this could be to design a new specific primer 5’ to the start codon of the Bcr-Abl gene in the 
pEYKBA vector. Hopefully will the vector-specific primer not misanneal, and a full-length 
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